{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:00:28Z","timestamp":1784984428004,"version":"3.55.0"},"reference-count":433,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10787-026-02295-2","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:22:04Z","timestamp":1781277724000},"page":"4551-4586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reprogramming immunity: the promise and challenges of CAR T cell therapy in multiple sclerosis"],"prefix":"10.1007","volume":"34","author":[{"given":"Nitik","family":"Kumawat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Upadhayay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"5","key":"2295_CR1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.trecan.2026.01.007","volume":"12","author":"A Aalipour","year":"2026","unstructured":"Aalipour A, Barreiro A, Garmilla A, Birnbaum ME (2026) vivo CAR T cell engineering: design principles and open questions. Trends Cancer 12(5):434\u2013446. https:\/\/doi.org\/10.1016\/j.trecan.2026.01.007","journal-title":"Trends Cancer"},{"issue":"2","key":"2295_CR2","doi-asserted-by":"publisher","first-page":"200980","DOI":"10.1016\/j.omton.2025.200980","volume":"3","author":"L Abdo","year":"2025","unstructured":"Abdo L, Batista-Silva LR, Bonamino MH (2025) Cost-effective strategies for CAR-T cell therapy manufacturing. Mol Therapy Oncol 3(2):200980. https:\/\/doi.org\/10.1016\/j.omton.2025.200980","journal-title":"Mol Therapy Oncol"},{"issue":"6","key":"2295_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1089\/hum.2005.16.741","volume":"16","author":"E Abordo-Adesida","year":"2005","unstructured":"Abordo-Adesida E, Follenzi A, Barcia C, Sciascia S, Castro MG, Naldini L, Lowenstein PR (2005) Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther 16(6):741\u2013751","journal-title":"Hum Gene Ther"},{"issue":"12","key":"2295_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11940-019-0601-2","volume":"21","author":"T Aboud","year":"2019","unstructured":"Aboud T, Schuster NM (2019) Pain management in multiple sclerosis: a review of available treatment options. Curr Treat options Neurol 21(12):62","journal-title":"Curr Treat options Neurol"},{"key":"2295_CR5","doi-asserted-by":"publisher","first-page":"1485799","DOI":"10.3389\/fneur.2024.1485799","volume":"15","author":"MA AbuAlrob","year":"2024","unstructured":"AbuAlrob MA, Mesraoua B (2024) Harnessing artificial intelligence for the diagnosis and treatment of neurological emergencies: a comprehensive review of recent advances and future directions. Front Neurol 15:1485799","journal-title":"Front Neurol"},{"issue":"2\u20133","key":"2295_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.14740\/wjon1345","volume":"12","author":"AA Adeniji","year":"2021","unstructured":"Adeniji AA, Dulal S, Martin MG (2021) Personalized medicine in oncology in the developing world: barriers and concepts to improve status quo. World J Oncol 12(2\u20133):50","journal-title":"World J Oncol"},{"issue":"15","key":"2295_CR7","doi-asserted-by":"publisher","first-page":"2409635","DOI":"10.1002\/smll.202409635","volume":"21","author":"A Adhikari","year":"2025","unstructured":"Adhikari A, Chen IA (2025) Antibody-Nanoparticle conjugates in therapy: combining the best of two worlds. Small 21(15):2409635","journal-title":"Small"},{"issue":"3","key":"2295_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.6004\/jadpro.2019.10.4.11","volume":"10","author":"S Adkins","year":"2019","unstructured":"Adkins S (2019) CAR T-cell therapy: adverse events and management. J Adv practitioner Oncol 10(3):21\u201328. https:\/\/doi.org\/10.6004\/jadpro.2019.10.4.11","journal-title":"J Adv practitioner Oncol"},{"key":"2295_CR9","doi-asserted-by":"publisher","first-page":"481125756","DOI":"10.1016\/j.jns.2026.125756","volume":"15","author":"S Aerts","year":"2026","unstructured":"Aerts S, Geys L, Severijns D, Alkhawajah M, Berger T, Boyko A, Oreja-Guevara C (2026) Directions for advancing prognostic assessments in multiple sclerosis: insights from MS specialists. J Neurol Sci 15:481125756. https:\/\/doi.org\/10.1016\/j.jns.2026.125756","journal-title":"J Neurol Sci"},{"key":"2295_CR10","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1182\/blood-2025-5504","volume":"146","author":"S Afridi","year":"2025","unstructured":"Afridi S, Shah Z, Shaukat A-a (2025) Comparative CRS risk across CAR-T constructs in DLBCL in real-world cohorts. Blood 146:5504","journal-title":"Blood"},{"issue":"1","key":"2295_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/2025.10.21.683607","volume":"2","author":"Y Aharony-Tevet","year":"2025","unstructured":"Aharony-Tevet Y, Ravid O, Yanir AD, Meir A, Levi H, Burstein D, Cooper I (2025) CAR T-cells dysfunction in the central nervous system is mediated by BBB-induced activation-induced cell death. BioRxiv 2(1):1\u201320. https:\/\/doi.org\/10.1101\/2025.10.21.683607","journal-title":"BioRxiv"},{"key":"2295_CR12","unstructured":"Aijaz M, Kumar R, Ahmad A, Raja S, Gupta MS, R. K., Yadav R The role of artificial intelligence in Parkinson\u2019s disease. Compr Rev 10(9):270\u2013279"},{"issue":"13","key":"2295_CR13","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.3390\/cancers17132163","volume":"17","author":"A Al-Kabani","year":"2025","unstructured":"Al-Kabani A, Huda B, Haddad J, Yousuf M, Bhurka F, Ajaz F, Banerjee Y (2025) Exploring experimental models of colorectal cancer: a critical appraisal from 2D cell systems to organoids, humanized mouse avatars, organ-on-chip, CRISPR engineering, and AI-driven platforms\u2014challenges and opportunities for translational precision oncology. Cancers 17(13):2163","journal-title":"Cancers"},{"key":"2295_CR14","doi-asserted-by":"crossref","unstructured":"Al-Worafi YM (2025) Evidence-based complementary, alternative, and integrated medicine and efficacy and safety: multiple sclerosis. handbook of complementary, alternative, and integrative medicine. CRC, pp 645\u2013664","DOI":"10.1201\/9781003328117-44"},{"issue":"6","key":"2295_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/art.43098","volume":"77","author":"MA Alba","year":"2025","unstructured":"Alba MA, Unizony S, Warrington KJ, Murgia G, Prieto-Gonz\u00e1lez S, Salvarani C, Kermani TA (2025) Management of relapses in giant cell arteritis. Arthritis Rheumatol 77(6):632\u2013645","journal-title":"Arthritis Rheumatol"},{"key":"2295_CR16","doi-asserted-by":"crossref","unstructured":"Albelo-Mart\u00ednez M, Rizvi S (2025) Progressive multiple sclerosis: evaluating current therapies and exploring future treatment strategies. Neurotherapeutics, e00601","DOI":"10.1016\/j.neurot.2025.e00601"},{"issue":"10","key":"2295_CR17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/17425255.2025.2566692","volume":"21","author":"M Alborghetti","year":"2025","unstructured":"Alborghetti M, Barbieri MA, Nicoletti F, Spina E (2025) Exploring drug interactions between newer antidepressants and medications used to treat neurological disorders. Expert Opin Drug Metab Toxicol 21(10):1169\u20131193","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2295_CR18","doi-asserted-by":"publisher","first-page":"1512494","DOI":"10.3389\/fimmu.2025.1512494","volume":"16","author":"HR Alfar","year":"2025","unstructured":"Alfar HR, Chen C, Lachacz E, Tang W, Zhang Y (2025) Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products. Front Immunol 16:1512494","journal-title":"Front Immunol"},{"key":"2295_CR19","doi-asserted-by":"publisher","first-page":"106453","DOI":"10.1016\/j.msard.2025.106453","volume":"99","author":"R Alonso","year":"2025","unstructured":"Alonso R, Eizaguirre MB, Casas M, Lazaro L, Laffue A, Mainella C, Rojas JI (2025) Determination of disability progression in moderately and highly disabled ambulatory patients with relapsing-remitting multiple sclerosis using the EDSS-Plus: a prospective study in Argentina. Multiple Scler Relat Disorders 99:106453","journal-title":"Multiple Scler Relat disorders"},{"key":"2295_CR20","doi-asserted-by":"publisher","first-page":"1615212","DOI":"10.3389\/fimmu.2025.1615212","volume":"16","author":"AA Alsaieedi","year":"2025","unstructured":"Alsaieedi AA, Zaher KA (2025) Tracing the development of CAR-T cell design: from concept to next-generation platforms. Front Immunol 16:1615212","journal-title":"Front Immunol"},{"key":"2295_CR21","doi-asserted-by":"publisher","first-page":"105009","DOI":"10.1016\/j.msard.2023.105009","volume":"79","author":"E Alvarez","year":"2023","unstructured":"Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM (2023) Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Multiple Scler Relat disorders 79:105009","journal-title":"Multiple Scler Relat disorders"},{"issue":"5","key":"2295_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Abou-el-Enein M (2022) Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat reviews Clin Oncol 19(5):342\u2013355","journal-title":"Nat reviews Clin Oncol"},{"issue":"1","key":"2295_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2767-9764.CRC-21-0034","volume":"1","author":"M Ando","year":"2021","unstructured":"Ando M, Kondo T, Tomisato W, Ito M, Shichino S, Srirat T, Yoshimura A (2021) Rejuvenating effector\/exhausted CAR T cells to stem cell memory\u2013like CAR T cells by resting them in the presence of CXCL12 and the NOTCH ligand. Cancer Res Commun 1(1):41\u201355","journal-title":"Cancer Res Commun"},{"key":"2295_CR24","doi-asserted-by":"crossref","unstructured":"Andreu-Sanz D, Gregor L, Carlini E, Scarcella D, Marr C, Kobold S (2025) Predictive value of preclinical models for CAR-T cell therapy clinical trials: a systematic review and meta-analysis. J Immunother Cancer, 13(6), e011698","DOI":"10.1136\/jitc-2025-011698"},{"issue":"5","key":"2295_CR25","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/brain\/awae409","volume":"148","author":"G Androdias","year":"2025","unstructured":"Androdias G, L\u00fcnemann JD, Maillart E, Amato MP, Audoin B, Bruijstens AL, Cobo-Calvo A (2025) De-escalating and discontinuing disease-modifying therapies in multiple sclerosis. Brain 148(5):1459\u20131478","journal-title":"Brain"},{"key":"2295_CR26","doi-asserted-by":"publisher","unstructured":"Antigny F, Crott\u00e8s D, Vandier C, Capuano V, Gu\u00e9guinou M (2025) Pulmonary arterial hypertension and cancer: exploring their resemblance as channelopathies. Trends Mol Med 31(10):936-954. https:\/\/doi.org\/10.1016\/j.molmed.2025.03.002","DOI":"10.1016\/j.molmed.2025.03.002"},{"issue":"11","key":"2295_CR27","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, Kadri JC (2021) Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27(11):1990\u20132001","journal-title":"Nat Med"},{"key":"2295_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3389\/fimmu.2018.00332","volume":"9","author":"L Aragoneses-Fenoll","year":"2018","unstructured":"Aragoneses-Fenoll L, Ojeda G, Montes-Casado M, Acosta-Ampudia Y, Dianzani U, Portol\u00e9s P, Rojo JM (2018) T-cell-specific loss of the PI-3-kinase p110\u03b1 catalytic subunit results in enhanced cytokine production and antitumor response. Front Immunol 9:332","journal-title":"Front Immunol"},{"issue":"2","key":"2295_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/biomedicines10020287","volume":"10","author":"M Arjomandnejad","year":"2022","unstructured":"Arjomandnejad M, Kopec AL, Keeler AM (2022) CAR-T regulatory (CAR-Treg) cells: engineering and applications. Biomedicines 10(2):287","journal-title":"Biomedicines"},{"issue":"1","key":"2295_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/neuroglia6010006","volume":"6","author":"AV Arredondo-Robles","year":"2025","unstructured":"Arredondo-Robles AV, Rodr\u00edguez-L\u00f3pez KP, \u00c1vila-Avil\u00e9s RD (2025) Clinical management in multiple sclerosis. Neuroglia 6(1):6","journal-title":"Neuroglia"},{"issue":"6","key":"2295_CR31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.cmet.2016.10.008","volume":"24","author":"RJ Arts","year":"2016","unstructured":"Arts RJ, Novakovic B, Ter Horst R, Carvalho A, Bekkering S, Lachmandas E, Wang S-Y (2016) Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metabol 24(6):807\u2013819","journal-title":"Cell Metabol"},{"issue":"4","key":"2295_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/curroncol32040198","volume":"32","author":"P Arvanitis","year":"2025","unstructured":"Arvanitis P, Tziotis A, Papadimatos S, Farmakiotis D (2025) Pathogenesis, diagnosis, and management of cytokine release syndrome in patients with cancer: focus on infectious disease considerations. Curr Oncol 32(4):198","journal-title":"Curr Oncol"},{"issue":"5","key":"2295_CR33","first-page":"1257","volume":"20","author":"MR Asgharzadeh Chamleh","year":"2025","unstructured":"Asgharzadeh Chamleh MR, Afkanpour M, Tehrany Dehkordy D, Norouzkhani N, Aalaei S (2025) Game-based telerehabilitation in neurological disorders: a systematic review of features, opportunities and challenges. Disabil Rehabilitation: Assist Technol 20(5):1257\u20131271","journal-title":"Disabil Rehabilitation: Assist Technol"},{"key":"2295_CR34","doi-asserted-by":"crossref","unstructured":"Atkinson KC, Desfor S, Feri M, Sekyi MT, Osunde M, Sriram S, Tiwari-Woodruff SK (2025) Decreased mitochondrial activity in the demyelinating cerebellum of progressive multiple sclerosis and chronic EAE contributes to Purkinje cell loss. Proc Natl Acad Sci 122(25), e2421806122","DOI":"10.1073\/pnas.2421806122"},{"issue":"5","key":"2295_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10616-025-00844-1","volume":"77","author":"G Aydogdu","year":"2025","unstructured":"Aydogdu G, Sermikli BP, Aras S, Yilmaz E (2025) The role of glutamine metabolism and ASCT2\/SLC1A5 transporter on insulin resistance and endoplasmic reticulum stress in 3T3-L1 adipocytes. Cytotechnology 77(5):177","journal-title":"Cytotechnology"},{"key":"2295_CR36","doi-asserted-by":"publisher","first-page":"1739021","DOI":"10.3389\/fneur.2026.1739021","volume":"17","author":"F Aziz","year":"2026","unstructured":"Aziz F, Chakraborty A, Saha D, Dutta P (2026) Immune effector cell-associated neurotoxicity syndrome: integrative mechanisms, predictive biomarkers, and translational pathways for prevention in CAR T-cell therapy. Front Neurol 17:1739021","journal-title":"Front Neurol"},{"key":"2295_CR37","doi-asserted-by":"publisher","first-page":"1617074","DOI":"10.3389\/fimmu.2025.1617074","volume":"16","author":"G Azizi","year":"2025","unstructured":"Azizi G, Rasouli J, Naziri H, Gonzalez MV, Garifallou J, Zhang G-X, Rostami A (2025) GM-CSF production by immune cells in steady state and autoimmune neuroinflammation mapped using fate reporting mice. Front Immunol 16:1617074","journal-title":"Front Immunol"},{"issue":"1","key":"2295_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s10571-025-01563-z","volume":"45","author":"B Babaalizadeh","year":"2025","unstructured":"Babaalizadeh B, Kalaki-Jouybari F, Abarghooi-Kahaki F, Afkhami H, Razavi Z-S (2025) Role of nuclear receptors on the progression of multiple sclerosis: a review. Cell Mol Neurobiol 45(1):58","journal-title":"Cell Mol Neurobiol"},{"key":"2295_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","volume":"16","author":"D Baker","year":"2017","unstructured":"Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K (2017) Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 16:41\u201350","journal-title":"EBioMedicine"},{"key":"2295_CR40","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.mito.2019.06.003","volume":"49","author":"N Baker","year":"2019","unstructured":"Baker N, Patel J, Khacho M (2019) Linking mitochondrial dynamics, cristae remodeling and supercomplex formation: How mitochondrial structure can regulate bioenergetics. Mitochondrion 49:259\u2013268","journal-title":"Mitochondrion"},{"key":"2295_CR41","doi-asserted-by":"crossref","unstructured":"Balashov A, Balashov V, Shikhanov N, Bystrova E, Gushchina S (2026) Expression of macrophage colony-stimulating factor 1 (CSF-1) by spinal cord astrocytes in mice with experimental autoimmune encephalomyelitis. Bull Exp Biol Med, pp 1\u20134","DOI":"10.1007\/s10517-026-06548-6"},{"issue":"3","key":"2295_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/neurosci6030087","volume":"6","author":"J Balconi","year":"2025","unstructured":"Balconi J, Langdon D, Dhakal B, Benedict RH (2025) An update on new approaches to cognitive assessment in multiple sclerosis. NeuroSci 6(3):87","journal-title":"NeuroSci"},{"issue":"1","key":"2295_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","volume":"16","author":"P Ballabh","year":"2004","unstructured":"Ballabh P, Braun A, Nedergaard M (2004) The blood\u2013brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16(1):1\u201313","journal-title":"Neurobiol Dis"},{"key":"2295_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/cen3.12576","volume":"11","author":"Y Bando","year":"2020","unstructured":"Bando Y (2020) Mechanism of demyelination and remyelination in multiple sclerosis. Clin Exp Neuroimmunol 11:14\u201321","journal-title":"Clin Experimental Neuroimmunol"},{"issue":"6","key":"2295_CR45","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","volume":"40","author":"AJ Barbier","year":"2022","unstructured":"Barbier AJ, Jiang AY, Zhang P, Wooster R, Anderson DG (2022) The clinical progress of mRNA vaccines and immunotherapies. Nat Biotechnol 40(6):840\u2013854","journal-title":"Nat Biotechnol"},{"key":"2295_CR46","doi-asserted-by":"crossref","unstructured":"Barbone AS, Giacomini T, Casabona S, De Grandis E, Sartore L, Calevo MG, Cellerino M (2026) First demyelinating attack in children: a twelve year single center cohort. Multiple Sclerosis Relat Disorders, p 107026","DOI":"10.1016\/j.msard.2026.107026"},{"issue":"1","key":"2295_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s43556-025-00401-4","volume":"7","author":"M Bayat","year":"2026","unstructured":"Bayat M, Nahand JS (2026) CAR-engineered cell therapies: current understandings and future perspectives. Mol Biomed 7(1):7","journal-title":"Mol Biomed"},{"issue":"11","key":"2295_CR48","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0b013e3181d55ee9","volume":"74","author":"K Bejaoui","year":"2010","unstructured":"Bejaoui K, Rolak LA (2010) What is the risk of permanent disability from a multiple sclerosis relapse? Neurology 74(11):900\u2013902","journal-title":"Neurology"},{"key":"2295_CR49","doi-asserted-by":"crossref","unstructured":"Belletti M, Izquierdo-Escamez R, Tornero C, Olivas-Vergara O, Peiteado D, Carre\u00f1o E (2025) Safe use of corticosteroids in non-infectious uveitis. J Inflamm Res, 14441\u201314455","DOI":"10.2147\/JIR.S540821"},{"key":"2295_CR50","doi-asserted-by":"publisher","first-page":"1664403","DOI":"10.3389\/fimmu.2025.1664403","volume":"16","author":"G Bernard","year":"2025","unstructured":"Bernard G, Evgin L (2025) Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together. Front Immunol 16:1664403","journal-title":"Front Immunol"},{"key":"2295_CR51","doi-asserted-by":"publisher","first-page":"123526","DOI":"10.1016\/j.jns.2025.123526","volume":"474","author":"S-G Berntsson","year":"2025","unstructured":"Berntsson S-G, Reis J, Zjukovskaja C, Tulek Z, Kristoffersson A, Landtblom A-M (2025) Climate change impacts the symptomology and healthcare of multiple sclerosis patients through fatigue and heat sensitivity-A systematic review. J Neurol Sci 474:123526","journal-title":"J Neurol Sci"},{"issue":"6","key":"2295_CR52","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/ana.25365","volume":"84","author":"RJ Bevan","year":"2018","unstructured":"Bevan RJ, Evans R, Griffiths L, Watkins LM, Rees MI, Magliozzi R, Naughton M (2018) Meningeal inflammation and cortical demyelination in acute multiple sclerosis. Ann Neurol 84(6):829\u2013842","journal-title":"Ann Neurol"},{"issue":"1","key":"2295_CR53","doi-asserted-by":"publisher","first-page":"ltaf003","DOI":"10.1093\/immadv\/ltaf003","volume":"5","author":"A Bibi","year":"2025","unstructured":"Bibi A, Yu Z, Cui L, Yang G (2025) Harnessing monocyte dynamics for treatment of multiple sclerosis; insights from experimental model studies. Immunotherapy Adv 5(1):ltaf003","journal-title":"Immunotherapy Adv"},{"key":"2295_CR54","doi-asserted-by":"publisher","unstructured":"Bielekova B, Wu T, Kosa P, Calcagni M (2026) Extrapolating from trials to clinic: a predictive model defining the boundaries of benefit for multiple sclerosis therapies in real-world populations based on systematic review. BMC Med 24(1):77. https:\/\/doi.org\/10.1186\/s12916-025-04603-z","DOI":"10.1186\/s12916-025-04603-z"},{"issue":"11","key":"2295_CR55","doi-asserted-by":"publisher","first-page":"2304378","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, Gong N, Mukalel AJ, Thatte AS, El-Mayta R, Patel SK, Xue L (2024) In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small 20(11):2304378","journal-title":"Small"},{"key":"2295_CR56","doi-asserted-by":"crossref","unstructured":"Binder LB, Bevilacqua M, Lorentzen Thomassen LG, Lebel F, Jensen M, Menard BA C (2025) Across barriers: blood\u2013brain and gut barrier signaling in psychiatric disorders. J Neurochem, 169(11), e70282","DOI":"10.1111\/jnc.70282"},{"key":"2295_CR57","unstructured":"BISWAS B Clinical outcomes of next-generation chimeric antigen receptor T-Cell therapy in acute lymphoblastic leukemia Volume 05 (2026), Version 02 pp. 69\u201376"},{"key":"2295_CR58","doi-asserted-by":"crossref","unstructured":"Blaylock B, Van Nuys K, Joyce G (2025) Formulary restrictions and relapse episodes in persons with relapsing-remitting multiple sclerosis. JAMA Netw Open, 8(8), e2525155","DOI":"10.1001\/jamanetworkopen.2025.25155"},{"issue":"1","key":"2295_CR59","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s44385-026-00072-y","volume":"3","author":"A Block","year":"2026","unstructured":"Block A, Liu X, Zhang D, Adebowale K (2026) Engineering macrophages for cancer immunotherapy: emerging insights and therapeutic potential. npj Biomed Innov 3(1):18","journal-title":"npj Biomedical Innovations"},{"key":"2295_CR60","doi-asserted-by":"crossref","unstructured":"Blud D, Rubio-Reyes P, Perret R, Weinkove R (2024) Tuning CAR T-cell therapies for efficacy and reduced toxicity. In: Seminars in hematology, vol 61, no 5. WB Saunders, pp 333-344","DOI":"10.1053\/j.seminhematol.2024.07.003"},{"issue":"4","key":"2295_CR61","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41571-025-00992-5","volume":"22","author":"TJ Bock","year":"2025","unstructured":"Bock TJ, Colonne CK, Fiorenza S, Turtle CJ (2025) Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma. Nat reviews Clin Oncol 22(4):241\u2013261","journal-title":"Nat reviews Clin Oncol"},{"key":"2295_CR62","doi-asserted-by":"publisher","first-page":"1543649","DOI":"10.3389\/fimmu.2025.1543649","volume":"16","author":"L Brieva","year":"2025","unstructured":"Brieva L, Calles C, Landete L, Oreja-Guevara C (2025) Current challenges in secondary progressive multiple sclerosis: diagnosis, activity detection and treatment. Front Immunol 16:1543649","journal-title":"Front Immunol"},{"issue":"7","key":"2295_CR63","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/blood.2023022682","volume":"144","author":"BJ Brinkmann","year":"2024","unstructured":"Brinkmann BJ, Floerchinger A, Schniederjohann C, Roider T, Coelho M, Mack N, Busch DH (2024) CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models. Blood 144(7):784\u2013789","journal-title":"Blood"},{"issue":"3","key":"2295_CR64","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/ana.27145","volume":"97","author":"WJ Brownlee","year":"2025","unstructured":"Brownlee WJ, Vidal-Jordana A, Shatila M, Strijbis E, Schoof L, Killestein J, Sastre\u2010Garriga J (2025) Towards a unified set of diagnostic criteria for multiple sclerosis. Ann Neurol 97(3):571\u2013582","journal-title":"Ann Neurol"},{"issue":"1","key":"2295_CR65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Kochenderfer JN (2018) Chimeric antigen receptor T-cell therapies for lymphoma. Nat reviews Clin Oncol 15(1):31\u201346","journal-title":"Nat reviews Clin Oncol"},{"issue":"7","key":"2295_CR66","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN (2024) Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol 21(7):501\u2013521","journal-title":"Nat reviews Clin Oncol"},{"issue":"5","key":"2295_CR67","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/jcm14051451","volume":"14","author":"AG Buciuc","year":"2025","unstructured":"Buciuc AG, Tran S, Weber M, Padilla V, Rueda-Lara M, Espinel Z (2025) Immune effector cell-associated neurotoxicity syndrome after CAR T-cell therapy and other psychiatric manifestations: a review and case series. J Clin Med 14(5):1451","journal-title":"J Clin Med"},{"issue":"20","key":"2295_CR68","doi-asserted-by":"publisher","first-page":"2404293","DOI":"10.1002\/adhm.202404293","volume":"14","author":"JC Burrell","year":"2025","unstructured":"Burrell JC, Ali ZS, Zager EL, Rosen JM, Tatarchuk MM, Cullen DK (2025) Engineering the future of restorative clinical peripheral nerve surgery. Adv Healthc Mater 14(20):2404293","journal-title":"Adv Healthc Mater"},{"issue":"2","key":"2295_CR69","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2018.18743","volume":"321","author":"RK Burt","year":"2019","unstructured":"Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Barreira AA (2019) Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA 321(2):165\u2013174","journal-title":"JAMA"},{"issue":"6","key":"2295_CR70","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/phn.70012","volume":"42","author":"S \u00c7akmak","year":"2025","unstructured":"\u00c7akmak S, Uzun S, Demir \u00c7am S (2025) Disease burden and sexual life in patients with multiple sclerosis: a phenomenological study. Public Health Nurs 42(6):1870\u20131879","journal-title":"Public Health Nurs"},{"issue":"7","key":"2295_CR71","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Hung S (2014) Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 13(7):657\u2013665","journal-title":"Lancet Neurol"},{"issue":"1","key":"2295_CR72","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1186\/s12887-025-06118-1","volume":"25","author":"L Cao","year":"2025","unstructured":"Cao L, Zhou M, Wei Z, Zhu R, Chen H, Zhou L, Wu S (2025a) Frontline therapy combining with intrathecal dexamethasone effectively alleviate immune effector cell-associated neurotoxicity syndrome in pediatric relapsed B-ALL receiving pCAR-19B-cases report. BMC Pediatr 25(1):738","journal-title":"BMC Pediatr"},{"issue":"9","key":"2295_CR73","doi-asserted-by":"publisher","first-page":"70059","DOI":"10.1002\/eji.70059","volume":"55","author":"S Cao","year":"2025","unstructured":"Cao S, Jiang J, Yin H, Su X, Li Q, Wu J, Lu Q (2025b) Aberrant nutrient metabolism in T cells: pathogenesis insight and therapeutic target for autoimmune diseases. Eur J Immunol 55(9):e70059","journal-title":"Eur J Immunol"},{"issue":"6","key":"2295_CR74","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat reviews Clin Oncol 20(6):359\u2013371","journal-title":"Nat reviews Clin Oncol"},{"issue":"1","key":"2295_CR75","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12974-025-03424-4","volume":"22","author":"EN Capper","year":"2025","unstructured":"Capper EN, Linton EF, Anders JJ, Kardon RH, Gramlich OW (2025) MOG35\u2009\u2013\u200955-induced EAE model of optic nerve inflammation compared to MS, MOGAD and NMOSD related subtypes of human optic neuritis. J Neuroinflamm 22(1):102","journal-title":"J Neuroinflamm"},{"issue":"1","key":"2295_CR76","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11926-025-01209-5","volume":"28","author":"DJ Carlson","year":"2026","unstructured":"Carlson DJ, Nichols LM, Moreland LW (2026) Emerging therapeutics in rheumatoid arthritis. Curr Rheumatol Rep 28(1):2","journal-title":"Curr Rheumatol Rep"},{"key":"2295_CR77","doi-asserted-by":"crossref","unstructured":"Carnero Contentti E, Correale J (2025) Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder, vol 30. Taylor & Francis, pp 71\u201375","DOI":"10.1080\/14728214.2025.2470706"},{"issue":"5","key":"2295_CR78","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.neurol.2025.03.008","volume":"181","author":"H Catenoix","year":"2025","unstructured":"Catenoix H, Grabon W, Rheims S, Vukusic S, Marignier R (2025) Multiple sclerosis and epilepsy. Rev Neurol 181(5):391\u2013396","journal-title":"Rev Neurol"},{"key":"2295_CR79","doi-asserted-by":"crossref","unstructured":"Ceccon M, Ronchi F (2026) Microbial\u2010immune interplay in cns autoimmune diseases: lessons from animal models and clinical studies. Euro J Immunol 56(2):e70135","DOI":"10.1002\/eji.70135"},{"key":"2295_CR80","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jad.2025.04.109","volume":"383","author":"H Chang","year":"2025","unstructured":"Chang H, Sun L, Wang X, Wang H, Shi Y (2025) Comparative efficacy of non-pharmacological interventions on depression in people with multiple sclerosis: a systematic review and network meta-analysis. J Affect Disord 383:207\u2013213","journal-title":"J Affect Disord"},{"key":"2295_CR81","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3389\/fimmu.2017.00473","volume":"8","author":"T Chao","year":"2017","unstructured":"Chao T, Wang H, Ho P-C (2017) Mitochondrial control and guidance of cellular activities of T cells. Front Immunol 8:473","journal-title":"Front Immunol"},{"issue":"1","key":"2295_CR82","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","volume":"20","author":"NM Chapman","year":"2020","unstructured":"Chapman NM, Boothby MR, Chi H (2020) Metabolic coordination of T cell quiescence and activation. Nat Rev Immunol 20(1):55\u201370","journal-title":"Nat Rev Immunol"},{"key":"2295_CR83","doi-asserted-by":"crossref","unstructured":"Chattha AJ, Porter SG, Fischer PR (2025) Functional disorders, chronic fatigue, chronic pain. adolescent medicine in the middle east: principles, perspectives, practices. Springer, pp 77\u201395","DOI":"10.1007\/978-3-032-12348-0_5"},{"key":"2295_CR84","doi-asserted-by":"crossref","unstructured":"Chen J, Liang T, Hu W, Liao N, Zhang Z, Shi H, Lin Y (2025a) Association between sarcopenia and the long-term risk of intervertebral disc degeneration. J Cachexia Sarcopenia Muscle, 16(5), e70086","DOI":"10.1002\/jcsm.70086"},{"key":"2295_CR85","doi-asserted-by":"publisher","first-page":"100112","DOI":"10.1016\/j.bmt.2025.100112","volume":"12","author":"J Chen","year":"2025","unstructured":"Chen J, Zhu X, Huo J, Wu S, Zhou T, Cheng C, Chen Y (2025b) A high-throughput immunopeptidome platform for MHC II alleles to characterize antigen-specific CD4\u2009+\u2009T cells. Biomedical Technol 12:100112","journal-title":"Biomedical Technol"},{"key":"2295_CR86","doi-asserted-by":"publisher","first-page":"1695461","DOI":"10.3389\/fneur.2025.1695461","volume":"16","author":"JY Chen","year":"2025","unstructured":"Chen JY, Sanghani N, Palmer K, Li Y, Lin F, Abbatemarco JR (2025c) Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies. Front Neurol 16:1695461","journal-title":"Front Neurol"},{"key":"2295_CR87","doi-asserted-by":"publisher","first-page":"1535002","DOI":"10.3389\/fmicb.2025.1535002","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen S, Yu Y, Su Y, Lian X, Jiang L, Li Z, Zhu X (2025d) Screening and identification of host signaling pathways for alleviating influenza-induced production of pro-inflammatory cytokines, IP-10, IL-8, and MCP-1, using a U937 cell-based influenza model. Front Microbiol 16:1535002","journal-title":"Front Microbiol"},{"key":"2295_CR88","doi-asserted-by":"crossref","unstructured":"Chen X, Lin P, Lu Y, Zheng J, Lin Y, Zhou Z, Zhao X (2025e) Mitochondrial regulation of CD8\u207a T cells: mechanisms and therapeutic modulation. Adv Sci, 12(32), e03095","DOI":"10.1002\/advs.202503095"},{"key":"2295_CR89","doi-asserted-by":"crossref","unstructured":"Chennuri RN, Yendapalli P, Chijioke C (2025) ABCL-080: A typical presentation of diffuse large B-Cell lymphoma (DLBCL) as heart failure exacerbation and refractory back pain with progressive renal and respiratory failure reflecting aggressive nature: a case report. Clinical Lymphoma Myeloma and Leukemia 25:S721","DOI":"10.1016\/S2152-2650(25)02228-1"},{"key":"2295_CR90","doi-asserted-by":"publisher","first-page":"1604174","DOI":"10.3389\/fimmu.2025.1604174","volume":"16","author":"NA Chinas","year":"2025","unstructured":"Chinas NA, Alexopoulos H (2025) CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy. Front Immunol 16:1604174","journal-title":"Front Immunol"},{"issue":"12","key":"2295_CR91","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","volume":"19","author":"A Chow","year":"2022","unstructured":"Chow A, Perica K, Klebanoff CA, Wolchok JD (2022) Clinical implications of T cell exhaustion for cancer immunotherapy. Nat Rev Clin Oncol 19(12):775\u2013790","journal-title":"Nat reviews Clin Oncol"},{"key":"2295_CR92","doi-asserted-by":"crossref","unstructured":"Cohen M, Rollot F, Debouverie M, Zephir H, Vukusic S, De Seze J, Levraut M (2025) Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study. Eur J Neurol, 32(5), e16583","DOI":"10.1111\/ene.16583"},{"key":"2295_CR93","doi-asserted-by":"crossref","unstructured":"Cook MS, King E, Flaherty KR, Siddika K, Papa S, Benjamin R, Schurich A (2025) CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients. Cell Reports 44(7)","DOI":"10.1016\/j.celrep.2025.115973"},{"key":"2295_CR94","doi-asserted-by":"crossref","unstructured":"Corrado M, Pearce EL (2022) Targeting memory T cell metabolism to improve immunity. J Clin Investig, 132(1)","DOI":"10.1172\/JCI148546"},{"issue":"4","key":"2295_CR95","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.24747","volume":"80","author":"B Cree","year":"2016","unstructured":"Cree B, Gourraud P, Oksenberg J, Bevan C, Crabtree-Hartman E, Gelfand J (2016) University of California, San Francisco MS-EPIC Team. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 80(4):499\u2013510","journal-title":"Ann Neurol"},{"issue":"6","key":"2295_CR96","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-025-01182-8","volume":"39","author":"BA Cree","year":"2025","unstructured":"Cree BA, Berger JR, Greenberg B (2025) The evolution of Anti-CD20 treatment for multiple sclerosis: optimization of antibody characteristics and function. CNS Drugs 39(6):545\u2013564","journal-title":"CNS Drugs"},{"issue":"5","key":"2295_CR97","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","volume":"97","author":"E Crickx","year":"2020","unstructured":"Crickx E, Weill J-C, Reynaud C-A, Mah\u00e9vas M (2020) Anti-CD20\u2013mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney Int 97(5):885\u2013893","journal-title":"Kidney Int"},{"key":"2295_CR98","volume-title":"T-cell specificity influences disease heterogeneity in multiple sclerosis","author":"C Cruciani","year":"2021","unstructured":"Cruciani C, Puthenparampil M, Tomas-Ojer P, Jelcic I, Docampo MJ, Planas R, Reindl M (2021) T-cell specificity influences disease heterogeneity in multiple sclerosis, vol 8. Neuroimmunology & Neuroinflammation, Neurology, 6e1075"},{"issue":"10","key":"2295_CR99","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s00520-025-09952-2","volume":"33","author":"MT Cruz Carreras","year":"2025","unstructured":"Cruz Carreras MT, Gonz\u00e1lez Landr\u00f3n F, L\u00f3pez N, Alc\u00e1ntara Padr\u00f3n, Markides L, Burk DM, K. J., Chaftari P (2025) Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review. Support Care Cancer 33(10):912","journal-title":"Support Care Cancer"},{"issue":"2","key":"2295_CR100","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11101-023-09867-y","volume":"24","author":"X Cui","year":"2025","unstructured":"Cui X, Lu J, Wei J, Zhao S, Yan Y, Yin G, Li P (2025) Single-chain variable fragment-based immunoassay for bioactive natural products. Phytochem Rev 24(2):1261\u20131281","journal-title":"Phytochem Rev"},{"key":"2295_CR101","doi-asserted-by":"publisher","first-page":"1363102","DOI":"10.3389\/fimmu.2024.1363102","volume":"15","author":"A Dabkowska","year":"2024","unstructured":"Dabkowska A, Domka K, Firczuk M (2024) Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells. Front Immunol 15:1363102","journal-title":"Front Immunol"},{"issue":"12","key":"2295_CR102","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Posey AD Jr (2023) Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol 24(12):1994\u20132007","journal-title":"Nat Immunol"},{"issue":"4","key":"2295_CR103","doi-asserted-by":"publisher","first-page":"qzaf077","DOI":"10.1093\/gpbjnl\/qzaf077","volume":"23","author":"R Dai","year":"2025","unstructured":"Dai R, Zhang M, Chu T, Kopp R, Zhang C, Liu K, Liu C (2025) Precision and accuracy in quantitative measurement of gene expression from single-cell\/nucleus RNA sequencing data. Genom Proteom Bioinform 23(4):qzaf077","journal-title":"Genom Proteom Bioinform"},{"key":"2295_CR104","doi-asserted-by":"publisher","first-page":"175628642614295","DOI":"10.1177\/17562864261429570","volume":"19","author":"MC Dalakas","year":"2026","unstructured":"Dalakas MC (2026) The prospects of CAR T-cell therapies in changing the therapeutic algorithm of neurologic autoimmunities. Ther Adv Neurol Disord 19:17562864261429570","journal-title":"Ther Adv Neurol Disord"},{"issue":"24","key":"2295_CR105","doi-asserted-by":"publisher","first-page":"2121804119","DOI":"10.1073\/pnas.2121804119","volume":"119","author":"V Damato","year":"2022","unstructured":"Damato V, Theorell J, Al-Diwani A, Kienzler A-K, Makuch M, Sun B, Ramanathan S (2022) Rituximab abrogates aquaporin-4\u2013specific germinal center activity in patients with neuromyelitis optica spectrum disorders. Proc Natl Acad Sci 119(24):e2121804119","journal-title":"Proc Natl Acad Sci"},{"key":"2295_CR106","doi-asserted-by":"publisher","first-page":"527882","DOI":"10.3389\/fimmu.2020.00442","volume":"11","author":"AS De Groot","year":"2020","unstructured":"De Groot AS, Moise L, Terry F, Gutierrez AH, Hindocha P, Richard G, Takahashi Y (2020) Better epitope discovery, precision immune engineering, and accelerated vaccine design using immunoinformatics tools. Front Immunol 11:527882","journal-title":"Front Immunol"},{"issue":"11","key":"2295_CR107","doi-asserted-by":"publisher","first-page":"e70397","DOI":"10.1111\/ene.70397","volume":"32","author":"AV De Keersmaecker","year":"2025","unstructured":"De Keersmaecker AV, Van Doninck E, Wens I, El Ouaamari Y, Popescu V, Laureys G, Derdelinckx J (2025) Recent advances in interventions targeting remyelination and a systematic review of remyelinating effects of approved disease-modifying treatments for multiple sclerosis. Eur J Neurol 32(11):e70397","journal-title":"Eur J Neurol"},{"issue":"8","key":"2295_CR108","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s00415-025-13283-x","volume":"272","author":"PH de Souza Wagner","year":"2025","unstructured":"de Souza Wagner PH, de Paiva FA, Mello JS, Silva ALM, Tanimoto LE, Tamashiro FM, de Almeida AM (2025) Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis. J Neurol 272(8):546","journal-title":"J Neurol"},{"issue":"5","key":"2295_CR109","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.tins.2025.01.003","volume":"48","author":"P Denno","year":"2025","unstructured":"Denno P, Zhao S, Husain M, Hampshire A (2025) Defining brain fog across medical conditions. Trends Neurosci 48(5):330\u2013348","journal-title":"Trends Neurosci"},{"issue":"4","key":"2295_CR110","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S1474-4422(19)30391-6","volume":"19","author":"T Derfuss","year":"2020","unstructured":"Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L (2020) Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol 19(4):336\u2013347","journal-title":"Lancet Neurol"},{"key":"2295_CR111","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL (2021) Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol 12:636568","journal-title":"Front Immunol"},{"key":"2295_CR112","doi-asserted-by":"crossref","unstructured":"Dhull P, Mishra R, Gupta A, Rana GJ, Sahoo S. Common neurological ailments across all ranks and maintaining mental health in today\u2019s stressful environment. InHealth and Sustenance in Extreme Environment: A Military Perspective 2025 Sep 1 (pp. 235-259). Singapore: Springer Nature Singapore.","DOI":"10.1007\/978-981-96-8642-1_14"},{"key":"2295_CR113","doi-asserted-by":"crossref","unstructured":"Dias de Sousa MA, Desid\u00e9rio CS, da Silva Catarino J, Trevisan RO, da Silva A, Rocha DA, da Silva VFR (2022) A. E. Role of cytokines, chemokines and IFN-\u03b3\u2009+\u2009IL-17\u2009+\u2009double-positive CD4\u2009+\u2009T cells in patients with multiple sclerosis. Biomedicines, 10(9), 2062","DOI":"10.3390\/biomedicines10092062"},{"issue":"7","key":"2295_CR114","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/diseases13070193","volume":"13","author":"AD Dic\u0103","year":"2025","unstructured":"Dic\u0103 AD, Craiu D, Linca FI, Budi\u0219teanu M, Iliescu C, Sandu C, Burloiu C (2025) Age-onset-related particularities of pediatric MS\u2014Understanding the spectrum: a tertiary center experience. Diseases 13(7):193","journal-title":"Diseases"},{"issue":"2","key":"2295_CR115","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/ijms26020467","volume":"26","author":"J Dingfelder","year":"2025","unstructured":"Dingfelder J, Taubmann J, von Heydebrand F, Aigner M, Bergmann C, Knitza J, Schett G (2025) Exploring CAR T-Cell dynamics: balancing potent cytotoxicity and controlled inflammation in CAR T-Cells derived from systemic sclerosis and myositis patients. Int J Mol Sci 26(2):467","journal-title":"Int J Mol Sci"},{"key":"2295_CR116","doi-asserted-by":"publisher","first-page":"1514813","DOI":"10.3389\/fimmu.2025.1514813","volume":"16","author":"M Dini","year":"2025","unstructured":"Dini M, Comi G, Leocani L (2025) Digital remote monitoring of people with multiple sclerosis. Front Immunol 16:1514813","journal-title":"Front Immunol"},{"key":"2295_CR117","doi-asserted-by":"crossref","unstructured":"Dong J, Nikolenko DA, Boymuradov S, Garifulina L, Khodabandehloo E (2026) Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology. Clin Transl Oncol, 1\u201327","DOI":"10.1007\/s12094-025-04185-5"},{"key":"2295_CR118","doi-asserted-by":"publisher","unstructured":"Donisan T, Balanescu DV, Abe JI, Lerman A, Iliescu CA, Herrmann J (2025) Vascular toxicities of cancer therapies: 2025 update. Arterioscler Thromb Vasc Biol 46(2):e319867. https:\/\/doi.org\/10.1161\/ATVBAHA.125.319867","DOI":"10.1161\/ATVBAHA.125.319867"},{"issue":"1","key":"2295_CR119","doi-asserted-by":"publisher","first-page":"2413778","DOI":"10.1080\/25310429.2024.2413778","volume":"31","author":"V Dourado","year":"2025","unstructured":"Dourado V (2025) Predicting maximum oxygen uptake using the six-minute walk distance in adults: what is the best curve fit estimation? Pulmonology 31(1):2413778","journal-title":"Pulmonology"},{"issue":"7","key":"2295_CR120","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/1744666X.2024.2349738","volume":"20","author":"A Dreyzin","year":"2024","unstructured":"Dreyzin A, Rankin AW, Luciani K, Gavrilova T, Shah NN (2024) Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy. Expert Rev Clin Immunol 20(7):745\u2013763","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2295_CR121","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12035-025-05632-8","volume":"63","author":"A Ebrahimbabaei","year":"2026","unstructured":"Ebrahimbabaei A, Osanloo M, Ghanbariasad A, Shojaeifard M (2026) Targeted drug delivery in animal models of demyelination: the role of plant-based nanoparticles with a focus on multiple sclerosis. Mol Neurobiol 63(1):344","journal-title":"Mol Neurobiol"},{"issue":"2","key":"2295_CR122","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/ajhp\/zxad247","volume":"81","author":"A Edinger","year":"2024","unstructured":"Edinger A, Habibi M (2024) The evolution of multiple sclerosis disease-modifying therapies: an update for pharmacists. Am J Health-System Pharm 81(2):37\u201355","journal-title":"Am J Health-System Pharm"},{"issue":"4","key":"2295_CR123","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1152\/physrev.00042.2022","volume":"103","author":"D Eisner","year":"2023","unstructured":"Eisner D, Neher E, Taschenberger H, Smith G (2023) Physiology of intracellular calcium buffering. Physiol Rev 103(4):2767\u20132845","journal-title":"Physiol Rev"},{"issue":"1","key":"2295_CR124","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s11481-025-10263-w","volume":"20","author":"S El Mahdaoui","year":"2025","unstructured":"El Mahdaoui S, Kosa P, Komori M, Veiga Gonz\u00e1lez JL, Chow HH, Ratzer R, Villar LM (2025) Profiling the cerebrospinal fluid proteome in progressive multiple sclerosis: treatment effects and associations with igM oligoclonal bands. J Neuroimmune Pharmacol 20(1):98","journal-title":"J Neuroimmune Pharmacol"},{"key":"2295_CR125","doi-asserted-by":"publisher","first-page":"1380654","DOI":"10.3389\/fneur.2024.1380654","volume":"15","author":"A Elgenidy","year":"2024","unstructured":"Elgenidy A, Abdelhalim NN, Al-Kurdi MA-M, Mohamed LA, Ghoneim MM, Fathy AW, Alomari O (2024) Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients. Front Neurol 15:1380654","journal-title":"Front Neurol"},{"issue":"6295","key":"2295_CR126","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Cotsarelis G (2016) Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353(6295):179\u2013184","journal-title":"Science"},{"issue":"2","key":"2295_CR127","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jtct.2024.12.002","volume":"31","author":"M Ellithi","year":"2025","unstructured":"Ellithi M, Elsallab M, Lunning MA, Holstein SA, Sharma S, Trinh JQ, D\u2019Angelo CR (2025) Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data. Transplantation Cell therapy 31(2):71 e71-71. e14","journal-title":"Transplantation Cell therapy"},{"issue":"11","key":"2295_CR128","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41409-020-0926-1","volume":"55","author":"VA Fabrizio","year":"2020","unstructured":"Fabrizio VA, Kernan NA, Boulad F, Cancio M, Allen J, Higman M, Scaradavou A (2020) Low toxicity and favorable overall survival in relapsed\/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplant 55(11):2160\u20132169","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"2295_CR129","doi-asserted-by":"publisher","first-page":"9944","DOI":"10.7150\/thno.121766","volume":"15","author":"S-S Fan","year":"2025","unstructured":"Fan S-S, Xu X, Luo Y-B, Meng X-Y, Liu Y (2025) GM-CSF\u2009+\u2009Th: a central player in autoimmunity. Theranostics 15(18):9944","journal-title":"Theranostics"},{"issue":"4","key":"2295_CR130","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41423-021-00808-3","volume":"19","author":"F Fang","year":"2022","unstructured":"Fang F, Xie S, Chen M, Li Y, Yue J, Ma J, Tian Z (2022) Advances in NK cell production. Cell Mol Immunol 19(4):460\u2013481","journal-title":"Cell Mol Immunol"},{"key":"2295_CR131","doi-asserted-by":"publisher","first-page":"100152","DOI":"10.1016\/j.jtauto.2022.100152","volume":"5","author":"C Fanton","year":"2022","unstructured":"Fanton C, Furie R, Chindalore V, Levin R, Diab I, Dixit N, Dickerson D (2022) Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus. J Translational Autoimmun 5:100152","journal-title":"J Translational Autoimmun"},{"issue":"1","key":"2295_CR132","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/ejh.70040","volume":"116","author":"D Farmakis","year":"2026","unstructured":"Farmakis D, Karampinos KI, Cordoba R, L\u00f3pez-Fern\u00e1ndez T, Filippatos G (2026) Predictive factors and baseline risk stratification for CAR\u2010T cell therapy\u2010related cardiovascular toxicity. Eur J Haematol 116(1):54\u201365","journal-title":"Eur J Haematol"},{"issue":"1","key":"2295_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.32598\/ptj.15.1.641.2","volume":"15","author":"L Fasihi","year":"2025","unstructured":"Fasihi L, Shahrbanian S, Jahangiri M (2025) Effects of combined training on fatigue in multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. Phys Treatments-Specific Phys Therapy J 15(1):1\u201314","journal-title":"Phys Treatments-Specific Phys Therapy J"},{"key":"2295_CR134","doi-asserted-by":"publisher","unstructured":"Fatahichegeni M, Ansarian MA, Wang Y, Ren J, Zhang T, Wang X (2025) Immune effector cell-associated neurotoxicity syndrome following CAR T-cell therapy: a review of recent advances. J Transl Med 24(1):114. https:\/\/doi.org\/10.1186\/s12967-025-07646-1","DOI":"10.1186\/s12967-025-07646-1"},{"key":"2295_CR135","doi-asserted-by":"crossref","unstructured":"Fedak RR, Ruggerie RN, Shan Y, Curvino EJ, de Sousa JF, Daniel S, Durmu\u015f H (2026) BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial. Nat Med, 1\u201313","DOI":"10.1038\/s41591-025-04170-z"},{"key":"2295_CR136","doi-asserted-by":"crossref","unstructured":"Ong MZ, Kimberly SA, Lee WH, Ling M, Lee M, Tan KW, Foo JB, Yow HY, Sellappans R, Hamzah S (2024) FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges. Curr Pharm Biotechnol 25(11):1377-93","DOI":"10.2174\/0113892010257212231001082741"},{"issue":"1","key":"2295_CR137","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1136\/jnnp-2025-336513","volume":"97","author":"YC Foong","year":"2026","unstructured":"Foong YC, Merlo D, Gresle M, Buzzard K, Horakova D, Havrdova EK, Lechner-Scott J (2026) Moderate\u2013high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis. J Neurol Neurosurg Psychiatry 97(1):50\u201358","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2295_CR138","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","volume":"9","author":"M Fransson","year":"2012","unstructured":"Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, Loskog AS (2012) CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflamm 9(1):112","journal-title":"J Neuroinflamm"},{"key":"2295_CR139","doi-asserted-by":"crossref","unstructured":"Frecska E, Kov\u00e1cs A, Szabo A (2025) The protective effect of DMT against neurodegeneration. In: International review of neurobiology (Vol. 181, pp. 395\u2013420). Elsevier","DOI":"10.1016\/bs.irn.2025.04.010"},{"issue":"4","key":"2295_CR140","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D (2019) Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 25(4):e123\u2013e127","journal-title":"Biol Blood Marrow Transplant"},{"key":"2295_CR141","doi-asserted-by":"crossref","unstructured":"Friedman AR, Gil-Perotin S, Wesley SF (2026) CAR T cell therapy: autoimmune neurological uses and neurotoxicities. Best Practice Res Clin Rheumatol, p 102145","DOI":"10.1016\/j.berh.2026.102145"},{"key":"2295_CR142","doi-asserted-by":"publisher","unstructured":"Galli E, Modoni A, Battistini L, Rossi M, Guerrera G, Pansini I, Corrente A, Hohaus S, Chiusolo P, Sor\u00e0 F, Calabresi P, Sica S (2026) Neuronal injury biomarkers GFAP and neurofilament light chains (NfL) are associated with neurotoxicity and endothelial dysfunction in adult patients treated with antiCD19 CART cells. Clin Exp Med. 26(1):121. https:\/\/doi.org\/10.1007\/s10238-026-02051-4. PMID: 41553539; PMCID: PMC12847193.","DOI":"10.1007\/s10238-026-02051-4"},{"issue":"5","key":"2295_CR143","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3390\/ijms26051886","volume":"26","author":"T Garcia-Mart\u00ednez","year":"2025","unstructured":"Garcia-Mart\u00ednez T, Gornatti DG, Ortiz M, Ca\u00f1ellas G, Heine-Su\u00f1er D, Vives-Bauz\u00e0 C (2025) The Triad of blood\u2013brain barrier integrity: endothelial cells, astrocytes, and pericytes in perinatal stroke pathophysiology. Int J Mol Sci 26(5):1886","journal-title":"Int J Mol Sci"},{"issue":"19","key":"2295_CR144","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1016\/j.neuron.2024.05.025","volume":"112","author":"T Garton","year":"2024","unstructured":"Garton T, Gadani SP, Gill AJ, Calabresi PA (2024) Neurodegeneration and demyelination in multiple sclerosis. Neuron 112(19):3231\u20133251","journal-title":"Neuron"},{"issue":"6","key":"2295_CR145","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00415-025-13173-2","volume":"272","author":"C Gasperini","year":"2025","unstructured":"Gasperini C, Centonze D, Conte A, Gallo P, Lugaresi A, Patti F, Filippi M (2025) Personalized therapy in multiple sclerosis: an Italian Delphi consensus. J Neurol 272(6):428","journal-title":"J Neurol"},{"issue":"2","key":"2295_CR146","first-page":"102357","volume":"19","author":"H Ge","year":"2026","unstructured":"Ge H, Zang T (2026) Evaluation efficacy of nicorandil combined with trimetazidine for unstable angina using Holter electrocardiography and serum biomarkers. J Radiation Res Appl Sci 19(2):102357","journal-title":"J Radiation Res Appl Sci"},{"issue":"6","key":"2295_CR147","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/bpa.12460","volume":"27","author":"R Geraldes","year":"2017","unstructured":"Geraldes R, Esiri MM, DeLuca GC, Palace J (2017) Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis. Brain Pathol 27(6):707\u2013722","journal-title":"Brain Pathol"},{"key":"2295_CR148","doi-asserted-by":"crossref","unstructured":"Selmaj K, Cree BA, Barnett M, Thompson A, Hartung HP (2024) Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol 271(1):105-15","DOI":"10.1007\/s00415-023-11969-8"},{"issue":"14","key":"2295_CR149","doi-asserted-by":"publisher","first-page":"11803","DOI":"10.3390\/ijms241411803","volume":"24","author":"L Giorgioni","year":"2023","unstructured":"Giorgioni L, Ambrosone A, Cometa MF, Salvati AL, Magrelli A (2023) CAR-T state of the art and future challenges, a regulatory perspective. Int J Mol Sci 24(14):11803","journal-title":"Int J Mol Sci"},{"key":"2295_CR150","doi-asserted-by":"crossref","unstructured":"Gklinos P, Mitsikostas DD (2026) Fatigue-associated variables in multiple sclerosis and affective drug treatment. In: The scientific basis of fatigue, Academic Press. pp 485-496","DOI":"10.1016\/B978-0-443-24080-5.00007-2"},{"issue":"1","key":"2295_CR151","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1038\/s41467-025-58274-8","volume":"16","author":"P Goebl","year":"2025","unstructured":"Goebl P, Wingrove J, Abdelmannan O, Brito Vega B, Stutters J, Ramos SDG, Arnold DL (2025) Enabling new insights from old scans by repurposing clinical MRI archives for multiple sclerosis research. Nat Commun 16(1):3149","journal-title":"Nat Commun"},{"issue":"1","key":"2295_CR152","doi-asserted-by":"publisher","first-page":"fcaf471","DOI":"10.1093\/braincomms\/fcaf471","volume":"8","author":"E Gofas-Salas","year":"2026","unstructured":"Gofas-Salas E, Mossad M, Beigneux Y, Norberg N, Castro Farias D, Vignal C, Grieve K (2026) In vivo characterization of a retinal cellular biomarker of inflammation in multiple sclerosis. Brain Commun 8(1):fcaf471","journal-title":"Brain Commun"},{"issue":"4","key":"2295_CR153","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ana.25315","volume":"84","author":"JS Gofshteyn","year":"2018","unstructured":"Gofshteyn JS, Shaw PA, Teachey DT, Grupp SA, Maude S, Banwell B, Edmonson MJ (2018) Neurotoxicity after CTL019 in a pediatric and young adult cohort. Ann Neurol 84(4):537\u2013546","journal-title":"Ann Neurol"},{"key":"2295_CR154","doi-asserted-by":"crossref","unstructured":"Gogula NSAR, Bharia U, AmaanullahMBBS M, Shahzaib M, Goel A, Roshaan M, Gogula NPR (2025) CT-1434: incidence of grade 3 or higher immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL): a systematic review and meta-analysis, vol 25. Clinical Lymphoma Myeloma and Leukemia, pp S1067\u2013S1068","DOI":"10.1016\/S2152-2650(25)02879-4"},{"key":"2295_CR155","doi-asserted-by":"crossref","unstructured":"Goodin DS, Khankhanian P, Gourraud P-A, Vince N (2018) Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility. PLoS ONE, 13(2), e0190043","DOI":"10.1371\/journal.pone.0190043"},{"issue":"7","key":"2295_CR156","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M, Miljkovi\u0107 MD, Chahin N, Sahagian G, Jewell CM (2023) Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol 22(7):578\u2013590","journal-title":"Lancet Neurol"},{"issue":"5","key":"2295_CR157","first-page":"685","volume":"13","author":"JM Griffin","year":"2025","unstructured":"Griffin JM, Grodin JL, Ruberg FL, Masri A, Hanna M, Maurer MS (2025) Current landscape of therapies for transthyretin amyloid cardiomyopathy. Heart Fail 13(5):685\u2013694","journal-title":"Heart Fail"},{"issue":"8","key":"2295_CR158","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.3390\/ijms26083532","volume":"26","author":"M Gryka-Marton","year":"2025","unstructured":"Gryka-Marton M, Grabowska AD, Szukiewicz D (2025) Breaking the barrier: the role of proinflammatory cytokines in BBB dysfunction. Int J Mol Sci 26(8):3532","journal-title":"Int J Mol Sci"},{"key":"2295_CR159","first-page":"106207","volume":"47","author":"M G\u00fcnd\u00fcz","year":"2025","unstructured":"G\u00fcnd\u00fcz M, Hematology (2025) Transfus Cell Therapy, 47, 106207","journal-title":"Transfus Cell Therapy"},{"issue":"2","key":"2295_CR160","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41401-025-01640-5","volume":"47","author":"H Guo","year":"2026","unstructured":"Guo H, Liu W-c, Sun Y-y, Jin X-c, Geng P-p (2026) Neuroglia and immune cells play different roles in neuroinflammation and neuroimmune response in post-stroke neural injury and repair. Acta Pharmacol Sin 47(2):273\u2013289","journal-title":"Acta Pharmacol Sin"},{"issue":"23Supplement2","key":"2295_CR161","first-page":"S32","volume":"99","author":"S Gupta","year":"2022","unstructured":"Gupta S, Simic M, Sagan S, Duecker J, Shepherd C, Sobel R, Zamvil S (2022) CAR-T cell-mediated B cell depletion in central nervous system autoimmunity. Neurology 99(23Supplement2):S32\u2013S32","journal-title":"Neurology"},{"key":"2295_CR162","volume-title":"CAR-T cell\u2013mediated B-cell depletion in central nervous system autoimmunity","author":"S Gupta","year":"2023","unstructured":"Gupta S, Simic M, Sagan SA, Shepherd C, Duecker J, Sobel RA, Pak JE (2023) CAR-T cell\u2013mediated B-cell depletion in central nervous system autoimmunity, vol 10. Neuroimmunology & Neuroinflammation, Neurology, 2e200080"},{"issue":"12","key":"2295_CR163","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, Lopez JA (2017) Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7(12):1404\u20131419","journal-title":"Cancer Discov"},{"key":"2295_CR164","doi-asserted-by":"publisher","unstructured":"Habibi MA, Zand A, Robat-Jazi B, Khodadadiyan A, Dashti M, Nejati N, Lorestan P, Karimizadeh Z, Ahmadpour M, Maleki F, Ahmadpour S (2026) The safety and efficacy of GD2-targeted CAR-T cells in patients with neuroblastoma: a systematic review and meta-analysis. Eur J Med Res 31(1):261. https:\/\/doi.org\/10.1186\/s40001-025-03764-0. PMID: 41530803; PMCID: PMC12888293.","DOI":"10.1186\/s40001-025-03764-0"},{"key":"2295_CR165","doi-asserted-by":"crossref","unstructured":"Haggiag S, Prosperini L, Filippi M, Rocca MA, Iaffaldano P, Patti F, Lus G (2025) Comparative effectiveness of cladribine and S1P receptor modulators in treatment-naive relapsing-remitting MS. JAMA Netw Open, 8(11), e2541025","DOI":"10.1001\/jamanetworkopen.2025.41025"},{"key":"2295_CR166","doi-asserted-by":"crossref","unstructured":"Hassankhani A, Bagley SJ, Dahmoush H, Parsons MS, Nabavizadeh A (2025) Role of neuroimaging in cancer-treatment neurotoxicity. Am J Roentgenol, 225(3):e2533139","DOI":"10.2214\/AJR.25.33139"},{"issue":"7","key":"2295_CR168","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Agarwal S (2008) B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis. N Engl J Med 358(7):676\u2013688","journal-title":"N Engl J Med"},{"issue":"3","key":"2295_CR167","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Selmaj K (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234","journal-title":"N Engl J Med"},{"issue":"3","key":"2295_CR169","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, Ellard R (2022) Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 33(3):259\u2013275","journal-title":"Ann Oncol"},{"issue":"2","key":"2295_CR170","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10571-022-01222-7","volume":"43","author":"Z He","year":"2023","unstructured":"He Z, Zhao Y, Sun J (2023) The role of major facilitator superfamily domain-containing 2a in the central nervous system. Cell Mol Neurobiol 43(2):639\u2013647","journal-title":"Cell Mol Neurobiol"},{"key":"2295_CR171","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/B978-0-323-90887-0.00016-X","volume":"214","author":"B Hemmer","year":"2026","unstructured":"Hemmer B (2026) Evolving targeted biologics against T cells, cytokines, and intracellular immune targets for multiple sclerosis with implications in other autoimmune neurologic diseases. Handb Clin Neurol 214:125\u2013142","journal-title":"Handb Clin Neurol"},{"key":"2295_CR172","doi-asserted-by":"publisher","first-page":"103057","DOI":"10.1016\/j.jaut.2023.103057","volume":"138","author":"P Henschel","year":"2023","unstructured":"Henschel P, Landwehr-Kenzel S, Engels N, Schienke A, Kremer J, Riet T, Redel N, Iordanidis K, Saetzler V, John K, Heider M, Hardtke-Wolenski M, Wedemeyer H, Jaeckel E, Noyan F. Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application. J Autoimmun. 2023 Jul;138:103057. https:\/\/doi.org\/10.1016\/j.jaut.2023.103057. Epub 2023 May 23. PMID: 37224732.","journal-title":"J Autoimmun"},{"issue":"11","key":"2295_CR173","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1073\/pnas.1920413117","volume":"117","author":"D Hermans","year":"2020","unstructured":"Hermans D, Gautam S, Garc\u00eda-Ca\u00f1averas JC, Gromer D, Mitra S, Spolski R, Lin J-X (2020) Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8\u2009+\u2009T cell stemness and antitumor immunity. Proc Natl Acad Sci 117(11):6047\u20136055","journal-title":"Proc Natl Acad Sci"},{"key":"2295_CR174","doi-asserted-by":"crossref","unstructured":"Hinckley-Boned A, Barbero-Jim\u00e9nez C, Trist\u00e1n-Manzano M, Maldonado-Perez N, Hudecek M, Justicia-Lirio P, Martin F (2025) Tailoring CAR surface density and dynamics to improve CAR-T cell therapy. J Immunother Cancer, 13(4), e010702","DOI":"10.1136\/jitc-2024-010702"},{"key":"2295_CR175","unstructured":"Hoofnagle JH. Mitoxantrone. 2025 Dec 4. In: LiverTox\u00ae: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012\u2013. PMID: 31643266."},{"issue":"6","key":"2295_CR176","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1016\/j.ymthe.2024.12.057","volume":"33","author":"H Hosseinalizadeh","year":"2025","unstructured":"Hosseinalizadeh H, Wang L-S, Mirzaei H, Amoozgar Z, Tian L, Yu J (2025) Emerging combined CAR-NK cell therapies in cancer treatment: finding a dancing partner. Mol Ther 33(6):2406\u20132425","journal-title":"Mol Ther"},{"issue":"12","key":"2295_CR177","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y (2021) Lipid nanoparticles for mRNA delivery. Nat Rev Mater 6(12):1078\u20131094","journal-title":"Nat Reviews Mater"},{"issue":"1","key":"2295_CR178","doi-asserted-by":"publisher","first-page":"eaeb6424","DOI":"10.1126\/sciadv.aeb6424","volume":"12","author":"X Huang","year":"2026","unstructured":"Huang X, Zhang Z, Liu D, Luo T, An X, Yang M, Cao J (2026) BCMA\/CD19 CAR T cell therapy for refractory myasthenia gravis: proteomic signatures and single-cell transcriptomics of disease flares. Sci Adv 12(1):eaeb6424","journal-title":"Sci Adv"},{"key":"2295_CR179","doi-asserted-by":"publisher","unstructured":"Hunter BD, Lunning M, Shadman M, Ahmed S, Abramson JS, Perales MA, Ahmed N, Mirza AS, Isufi I, Frigault MJ, Crombie JL, Miklos DB, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini MC, Kamdar M (2025) CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting. Transplant Cell Ther. 2026 Feb;32(2):171.e1-171.e12. https:\/\/doi.org\/10.1016\/j.jtct.2025.10.024. Epub 2025 Oct 24. PMID: 41235976; PMCID: PMC13012614.","DOI":"10.1016\/j.jtct.2025.10.024"},{"key":"2295_CR180","doi-asserted-by":"publisher","unstructured":"Iglesias-Lopez C, Vallano A, Agust\u00ed A (2026) Outlook of Cell Gene Therapies Development and Approval from Quality and Regulatory Perspective. Ther Innov Regul Sci. 2026 May;60(3):823-836. https:\/\/doi.org\/10.1007\/s43441-026-00920-4. Epub 2026 Feb 12. PMID: 41678030; PMCID: PMC13110239.","DOI":"10.1007\/s43441-026-00920-4"},{"key":"2295_CR181","doi-asserted-by":"crossref","unstructured":"Ikoma Y, Nakamura N, Kitagawa J, Hayase N, Takada E, Matsumoto T, Lee S (2026) Gemcitabine, carboplatin, dexamethasone, and rituximab versus high-dose cytarabine\u2010based chemotherapy as second\u2010line treatments for relapsed or refractory diffuse large B\u2010cell lymphoma. Hematol Oncol 44(1):e70164","DOI":"10.1002\/hon.70164"},{"key":"2295_CR182","doi-asserted-by":"publisher","unstructured":"Urooj Imdad, Farzana Tariq, Petrica Molnar, Joli S. Forgach, HusamEddin Salama, Yusuf-Zain Ansari, Jeni Page, Dia R. Halalmeh, Chapter Thirteen - Pain management and rehabilitation, Editor(s): Dia R. Halalmeh, Marc D. Moisi, Osteomyelitis and Discitis of the Spine, Academic Press, 2025, Pages 429-442, ISBN 9780443191336, https:\/\/doi.org\/10.1016\/B978-0-443-19133-6.00013-4.","DOI":"10.1016\/B978-0-443-19133-6.00013-4"},{"issue":"9","key":"2295_CR183","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41568-025-00832-9","volume":"25","author":"CJ Imianowski","year":"2025","unstructured":"Imianowski CJ, Chen Q, Workman CJ, Vignali DA (2025) Regulatory T cells in the tumour microenvironment. Nat Rev Cancer 25(9):703\u2013722","journal-title":"Nat Rev Cancer"},{"key":"2295_CR184","doi-asserted-by":"publisher","first-page":"1683546","DOI":"10.3389\/fendo.2025.1683546","volume":"16","author":"Y Ishibashi","year":"2025","unstructured":"Ishibashi Y, Baba R, Okada A, Otagaki Y, Kodama T, Egusa G, Ono A (2025) Normal adrenocorticotropic hormone levels do not exclude adrenal insufficiency during immune checkpoint inhibitor therapy: evidence from clinical, steroid, and structural analyses. Front Endocrinol 16:1683546","journal-title":"Front Endocrinol"},{"issue":"20","key":"2295_CR185","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN (2023) How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood J Am Soc Hematol 141(20):2430\u20132442","journal-title":"Blood J Am Soc Hematol"},{"issue":"30","key":"2295_CR186","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1200\/JCO.23.02786","volume":"42","author":"MD Jain","year":"2024","unstructured":"Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, McGuirk J (2024) Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol 42(30):3581\u20133592","journal-title":"J Clin Oncol"},{"key":"2295_CR187","doi-asserted-by":"publisher","first-page":"115597","DOI":"10.1016\/j.intimp.2025.115597","volume":"166","author":"MC Jamali","year":"2025","unstructured":"Jamali MC, Gaffer AGM, Hassan HG, Ali SA, Sulaiman MK, Tariq A, Mansuri N, Dutta AK, Mudhafar M. Engineering scFv immunotherapies: From CAR T cells to bispecific antibodies. Int Immunopharmacol. 2025 Dec 3;166:115597. https:\/\/doi.org\/10.1016\/j.intimp.2025.115597. Epub 2025 Sep 29. PMID: 41027062.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"2295_CR188","first-page":"129","volume":"46","author":"JU Jang","year":"2025","unstructured":"Jang JU, Choi EP, Cho KH (2025) Effect of active over-ground body weight-support walking system on balance and gait ability in stroke: A randomized controlled trial. Physiotherapy Pract Res 46(2):129\u2013137","journal-title":"Physiotherapy Pract Res"},{"key":"2295_CR189","doi-asserted-by":"publisher","unstructured":"Jankovi\u0107 SM. Clinical advances in investigational epilepsy treatments. Expert Opin Investig Drugs. 2025 Oct;34(10):737-743. https:\/\/doi.org\/10.1080\/13543784.2025.2574992. Epub 2025 Oct 14. PMID: 41082250.","DOI":"10.1080\/13543784.2025.2574992"},{"key":"2295_CR190","unstructured":"Jansky J, Breitung H, D\u00f6ngi L, Wentzel F, Picard D, K\u00fcchler N, Thurner L (2026) R-CHOP for non-Hodgkin lymphoma: Its effects on cancer cells, NK cell viability and cytotoxicity against B-lymphoma cell lines. BioRxiv, 2026.2001. 2012.698321"},{"key":"2295_CR191","doi-asserted-by":"crossref","unstructured":"Jenner AL, Weatherley GR, Frascoli F (2025) A mathematical model for inflammation and demyelination in multiple sclerosis. BioRxiv, 2025.2007. 2031.667831","DOI":"10.1101\/2025.07.31.667831"},{"key":"2295_CR192","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","volume":"33","author":"MC Jensen","year":"2015","unstructured":"Jensen MC, Riddell SR (2015) Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 33:9\u201315","journal-title":"Curr Opin Immunol"},{"issue":"15","key":"2295_CR193","doi-asserted-by":"publisher","first-page":"6884","DOI":"10.7150\/ijbs.124144","volume":"21","author":"Z Jia","year":"2025","unstructured":"Jia Z, Wu J, Zhang J, Zheng P, Zhang H, Lin Y, Song Y (2025) Precision Reprogramming in CAR-T Cell Therapy: Innovations, Challenges, and Future Directions of Advanced Gene Editing. Int J Biol Sci 21(15):6884","journal-title":"Int J Biol Sci"},{"key":"2295_CR194","doi-asserted-by":"publisher","unstructured":"Jones J (2025) The impact of inflammatory context on the metabolic profile of T follicular helper cells. University of Glasgow]. https:\/\/doi.org\/10.5525\/gla.thesis.85596","DOI":"10.5525\/gla.thesis.85596"},{"issue":"1","key":"2295_CR195","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","volume":"14","author":"LV J\u00f8rgensen","year":"2025","unstructured":"J\u00f8rgensen LV, Christensen EB, Barnkob MB, Barington T (2025) The clinical landscape of CAR NK cells. Experimental Hematol Oncol 14(1):46","journal-title":"Experimental Hematol Oncol"},{"issue":"2","key":"2295_CR196","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11912-024-01634-2","volume":"27","author":"T Joseph","year":"2025","unstructured":"Joseph T, Sanchez J, Abbasi A, Zhang L, Sica RA, Duong TQ (2025) Cardiotoxic effects following CAR-T cell therapy: a literature review. Curr Oncol Rep 27(2):135\u2013147","journal-title":"Curr Oncol Rep"},{"issue":"482","key":"2295_CR197","doi-asserted-by":"publisher","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","volume":"11","author":"R Kansal","year":"2019","unstructured":"Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, Giorgianni F (2019) Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med 11(482):eaav1648","journal-title":"Sci Transl Med"},{"key":"2295_CR198","doi-asserted-by":"publisher","unstructured":"Karadeniz M, Wesselingh R, Jayakrishnan PC, Sequeira RP, Van Der Walt A, Butzkueven H, Monif M. Innate immunity and biomarkers of multiple sclerosis relapse versus remission. Autoimmun Rev. 2026 Jun;25(6):104058. https:\/\/doi.org\/10.1016\/j.autrev.2026.104058. Epub 2026 Apr 16. PMID: 42000092.","DOI":"10.1016\/j.autrev.2026.104058"},{"key":"2295_CR199","doi-asserted-by":"publisher","first-page":"153477","DOI":"10.1016\/j.prp.2021.153477","volume":"223","author":"G Karpathiou","year":"2021","unstructured":"Karpathiou G, Papoudou-Bai A, Ferrand E, Dumollard JM, Peoc\u2019h M (2021) STAT6: a review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology. Pathology-Research Pract 223:153477","journal-title":"Pathology-Research Pract"},{"issue":"8","key":"2295_CR200","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41582-025-01112-8","volume":"21","author":"P Karschnia","year":"2025","unstructured":"Karschnia P, Dietrich J (2025) Neurological complications of CAR T cell therapy for cancers. Nat Reviews Neurol 21(8):422\u2013431","journal-title":"Nat Reviews Neurol"},{"key":"2295_CR201","doi-asserted-by":"publisher","first-page":"106401","DOI":"10.1016\/j.msard.2025.106401","volume":"97","author":"E Kaya","year":"2025","unstructured":"Kaya E, Aslan T, \u015eim\u015fek Y, Ozcelik S, Ozakbas S (2025) The role of pregnancy in relapsing-remitting MS prognosis: A five-year study. Multiple Scler Relat disorders 97:106401","journal-title":"Multiple Scler Relat disorders"},{"issue":"1","key":"2295_CR202","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/acr.25694","volume":"78","author":"EM Kelleher","year":"2026","unstructured":"Kelleher EM, Meouchi R, Irani A (2026) Beyond inflammation: why understanding the brain matters in inflammatory arthritis. Arthritis Care Res 78(1):3\u201314","journal-title":"Arthritis Care Res"},{"key":"2295_CR203","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.msard.2017.08.011","volume":"17","author":"C Keytsman","year":"2017","unstructured":"Keytsman C, Eijnde BO, Hansen D, Verboven K, Wens I (2017) Elevated cardiovascular risk factors in multiple sclerosis. Multiple Scler Relat disorders 17:220\u2013223","journal-title":"Multiple Scler Relat disorders"},{"issue":"6","key":"2295_CR204","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.ymthe.2025.01.035","volume":"33","author":"M Khalifeh","year":"2025","unstructured":"Khalifeh M, Salman H (2025) Engineering resilient CAR T cells for immunosuppressive environment. Mol Ther 33(6):2391\u20132405","journal-title":"Mol Ther"},{"key":"2295_CR205","doi-asserted-by":"publisher","first-page":"707542","DOI":"10.3389\/fimmu.2021.707542","volume":"12","author":"MB Khawar","year":"2021","unstructured":"Khawar MB, Sun H (2021) CAR-NK cells: from natural basis to design for kill. Front Immunol 12:707542","journal-title":"Front Immunol"},{"key":"2295_CR206","doi-asserted-by":"publisher","first-page":"121339","DOI":"10.1016\/j.biomaterials.2021.121339","volume":"281","author":"A Kheirolomoom","year":"2022","unstructured":"Kheirolomoom A, Kare AJ, Ingham ES, Paulmurugan R, Robinson ER, Baikoghli M, Fite BZ (2022) In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift. Biomaterials 281:121339","journal-title":"Biomaterials"},{"key":"2295_CR208","doi-asserted-by":"publisher","unstructured":"Kim S, Heo SH, Baek H, Hwang SS. Cytokine Engineering in CAR-T Cell Therapy: Next-Generation Strategies. Immune Netw. 2025 Dec 18;25(6):e43. https:\/\/doi.org\/10.4110\/in.2025.25.e43. PMID: 41523142; PMCID: PMC12780155.","DOI":"10.4110\/in.2025.25.e43"},{"key":"2295_CR207","doi-asserted-by":"publisher","unstructured":"Kim S, Ahn KW, Logan B, Brazauskas R, Chen M, Pasquini M, Moskop A. Statistical Methods for Chimeric Antigen Receptor Cell Therapy Outcomes: A Review and Practical Considerations. Transplant Cell Ther. 2026 Mar 17:S2666-6367(26)00224-1. https:\/\/doi.org\/10.1016\/j.jtct.2026.03.016. Epub ahead of print. PMID: 41856319; PMCID: PMC13171207.","DOI":"10.1016\/j.jtct.2026.03.016"},{"key":"2295_CR209","doi-asserted-by":"crossref","unstructured":"Klebanoff CA, Crompton JG, Leonardi AJ, Yamamoto TN, Chandran SS, Eil RL, Ji Y (2017) Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight, 2(23), e95103","DOI":"10.1172\/jci.insight.95103"},{"key":"2295_CR210","doi-asserted-by":"crossref","unstructured":"Klebe G (2025) Biologicals: peptides, proteins, nucleotides, and macrolides as drugs. Drug Design: from structure and mode-of-action to rational design concepts. Springer, pp 625\u2013653","DOI":"10.1007\/978-3-662-68998-1_32"},{"key":"2295_CR211","doi-asserted-by":"publisher","first-page":"175628642513727","DOI":"10.1177\/17562864251372752","volume":"18","author":"L Klotz","year":"2025","unstructured":"Klotz L, Berger T, Brownlee WJ, Chan A, Lycke J, Oreja-Guevara C, Weber MS (2025) Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook. Ther Adv Neurol Disord 18:17562864251372752","journal-title":"Ther Adv Neurol Disord"},{"key":"2295_CR212","doi-asserted-by":"publisher","first-page":"103029","DOI":"10.1016\/j.msard.2021.103029","volume":"53","author":"N Koch-Henriksen","year":"2021","unstructured":"Koch-Henriksen N, S\u00f8rensen PS, Magyari M (2021) Relapses add to permanent disability in relapsing multiple sclerosis patients. Multiple Scler Relat disorders 53:103029","journal-title":"Multiple Scler Relat disorders"},{"issue":"1","key":"2295_CR213","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s42466-025-00414-y","volume":"7","author":"FF Konen","year":"2025","unstructured":"Konen FF, Witte T, Ernst D, Hagin D, Jendretzky KF, M\u00f6hn N, Klotz L (2025) Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis. Neurol Res Pract 7(1):48","journal-title":"Neurol Res Pract"},{"issue":"6","key":"2295_CR214","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/jnr.24114","volume":"96","author":"TJ Kopper","year":"2018","unstructured":"Kopper TJ, Gensel JC (2018) Myelin as an inflammatory mediator: Myelin interactions with complement, macrophages, and microglia in spinal cord injury. J Neurosci Res 96(6):969\u2013977","journal-title":"J Neurosci Res"},{"key":"2295_CR215","doi-asserted-by":"publisher","unstructured":"Kourlaba G, Koutsis G, Fakas N, Tsimourtou V, Karachalios G, Bakirtzis C, Grigoriadis N. The economic impact, healthcare resource utilization, and clinical outcome over 24\u2009months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- The Fidelity Study. Expert Rev Pharmacoecon Outcomes Res. 2026 Feb;26(2):231-241. https:\/\/doi.org\/10.1080\/14737167.2025.2603955. Epub 2025 Dec 18. PMID: 41390331.","DOI":"10.1080\/14737167.2025.2603955"},{"issue":"6","key":"2295_CR216","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/ejh.13170","volume":"101","author":"K Kriegsmann","year":"2018","unstructured":"Kriegsmann K, Kriegsmann M, von Bergwelt-Baildon M, Cremer M, Witzens\u2010Harig M (2018) NKT cells\u2014New players in CAR cell immunotherapy? Eur J Haematol 101(6):750\u2013757","journal-title":"Eur J Haematol"},{"issue":"5","key":"2295_CR217","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2174\/1874467214666210301121432","volume":"14","author":"N Kumar","year":"2021","unstructured":"Kumar N, Sharma N, Mehan S (2021) Connection between JAK\/STAT and PPAR\u03b3 signaling during the progression of multiple sclerosis: Insights into the modulation of T-cells and immune responses in the brain. Curr Mol Pharmacol 14(5):823\u2013837","journal-title":"Curr Mol Pharmacol"},{"issue":"7","key":"2295_CR218","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1007\/s43032-025-01900-z","volume":"32","author":"R Kumar","year":"2025","unstructured":"Kumar R, Vats P, Panchal P, Kumar S (2025) Phospholipases: paving the way for a new life. Reproductive Sci 32(7):2080\u20132097","journal-title":"Reproductive Sci"},{"issue":"2","key":"2295_CR219","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/ijms27020585","volume":"27","author":"V Kurilin","year":"2026","unstructured":"Kurilin V, Fisher M, Obleukhova I, Sennikov S (2026) Cellular immunotherapies for multiple sclerosis: mechanistic insights and clinical advances. Int J Mol Sci 27(2):585","journal-title":"Int J Mol Sci"},{"key":"2295_CR220","doi-asserted-by":"publisher","unstructured":"Kurtovic, Zerina (2025) Peripheral neuroimmune interactions in health and arthritis-induced pain. Karolinska Institutet. Thesis. https:\/\/doi.org\/10.69622\/28929746","DOI":"10.69622\/28929746"},{"key":"2295_CR221","doi-asserted-by":"crossref","unstructured":"Kushwaha M, Kumar V, Khodlan P, Verma S, Teotia A, Singh R, Kumar A (2026) Adverse effects of CAR T-cell therapy and management: cytokine release syndrome and neurotoxicity. advancement in CAR T-cell therapy in tumors: current challenges and future directions. Springer, pp 137\u2013152","DOI":"10.1007\/978-981-95-3628-3_6"},{"issue":"5","key":"2295_CR222","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/bioengineering10050519","volume":"10","author":"A \u0141ach","year":"2023","unstructured":"\u0141ach A, Wnuk A, W\u00f3jtowicz AK (2023) Experimental models to study the functions of the blood\u2013brain barrier. Bioengineering 10(5):519","journal-title":"Bioengineering"},{"issue":"1","key":"2295_CR224","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1038\/s41467-025-59786-z","volume":"16","author":"Y Lai","year":"2025","unstructured":"Lai Y, Wang S, Ren T, Shi J, Qian Y, Wang S, Ruan X (2025) TIGIT deficiency promotes autoreactive CD4\u2009+\u2009T-cell responses through a metabolic\u2013epigenetic mechanism in autoimmune myositis. Nat Commun 16(1):4502","journal-title":"Nat Commun"},{"issue":"1","key":"2295_CR223","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41392-025-02533-z","volume":"11","author":"L Lai","year":"2026","unstructured":"Lai L, Ran S, Li Y, Cui J, Zhang X, Yu J, Wu J (2026) Cytotoxic CD4\u2009+\u2009T cells: origin, biological functions, diseases and therapeutic targets. Signal Transduct Target Therapy 11(1):85","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"2295_CR225","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","volume":"11","author":"N Lam","year":"2020","unstructured":"Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N, Kochenderfer JN (2020) Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat Commun 11(1):283","journal-title":"Nat Commun"},{"key":"2295_CR226","doi-asserted-by":"publisher","first-page":"175628642514044","DOI":"10.1177\/17562864251404464","volume":"19","author":"A Lasocki","year":"2026","unstructured":"Lasocki A, Harrison SJ, Dickinson M, Kalincik T (2026) The role of neuroimaging in neurotoxicity after chimeric antigen receptor T-cell therapy. Ther Adv Neurol Disord 19:17562864251404464","journal-title":"Ther Adv Neurol Disord"},{"key":"2295_CR227","doi-asserted-by":"crossref","unstructured":"Lattanzio MV, Jurgens AP, Hoogendijk AJ, van der Zwaan C, Wardak L, Bresser K, Wolkers MC (2026) An early mTOR-dependent window during human T cell activation programs T cell state. BioRxiv, 2026.2001. 2029.702520","DOI":"10.64898\/2026.01.29.702520"},{"issue":"3","key":"2295_CR228","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/08830738251361701","volume":"41","author":"A Layton","year":"2026","unstructured":"Layton A, Sattar S, Rho JM, Yang JH, Gold J, Zimbric M, Frederick A (2026) Vigabatrin versus adrenocorticotropic hormone after high-dose prednisolone failure for the treatment of epileptic spasms. J Child Neurol 41(3):359\u2013364","journal-title":"J Child Neurol"},{"issue":"4","key":"2295_CR229","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Pavletic S (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"key":"2295_CR230","doi-asserted-by":"publisher","first-page":"154569","DOI":"10.1016\/j.phymed.2022.154569","volume":"112","author":"J-I Lee","year":"2023","unstructured":"Lee J-I, Choi J-H, Kwon T-W, Jo H-S, Kim D-G, Ko S-G, Cho I-H (2023) Neuroprotective effects of bornyl acetate on experimental autoimmune encephalomyelitis via anti-inflammatory effects and maintaining blood-brain-barrier integrity. Phytomedicine 112:154569","journal-title":"Phytomedicine"},{"issue":"4","key":"2295_CR233","doi-asserted-by":"publisher","first-page":"a029108","DOI":"10.1101\/cshperspect.a029108","volume":"9","author":"R Li","year":"2019","unstructured":"Li R, Bar-Or A (2019) The multiple roles of B cells in multiple sclerosis and their implications in multiple sclerosis therapies. Cold Spring Harbor Perspect Med 9(4):a029108","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"4","key":"2295_CR231","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ (2020) Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet 21(4):255\u2013272","journal-title":"Nat Rev Genet"},{"key":"2295_CR238","doi-asserted-by":"publisher","unstructured":"Li Y, Wang L. Bidirectional Regulation in the Tumour Microenvironment: The Interaction Between Tumour-Associated Macrophages and T Cells Reshapes the Paradigm of Cancer Immunotherapy. Immunology. 2026 May;178(1):1-22. https:\/\/doi.org\/10.1111\/imm.70103. Epub 2026 Jan 7. PMID: 41498784.","DOI":"10.1111\/imm.70103"},{"key":"2295_CR236","doi-asserted-by":"publisher","unstructured":"Li YR, Yang L. Autologous, allogeneic, in vivo CAR for autoimmune diseases. Trends Pharmacol Sci. 2026 Jan;47(1):11-14. https:\/\/doi.org\/10.1016\/j.tips.2025.11.001. Epub 2025 Nov 25. PMID: 41298149.","DOI":"10.1016\/j.tips.2025.11.001"},{"issue":"1","key":"2295_CR235","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13287-022-02787-2","volume":"13","author":"Y-R Li","year":"2022","unstructured":"Li Y-R, Dunn ZS, Garcia Jr G, Carmona C, Zhou Y, Lee D, Arumugaswami V (2022) Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. Stem Cell Res Ther 13(1):112","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"2295_CR237","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","volume":"25","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Zhu Y, Halladay T, Yang L (2025) vivo CAR engineering for immunotherapy. Nat Rev Immunol 25(10):725\u2013744","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2295_CR232","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.4103\/NRR.NRR-D-24-01539","volume":"21","author":"K Li","year":"2026","unstructured":"Li K, Chen R, Wang R, Fan W, Zhao N, Yang Z, Yan J (2026a) Neuroinflammation in neurodegenerative diseases: Focusing on the mediation of T lymphocytes. Neural regeneration Res 21(5):1864\u20131889","journal-title":"Neural regeneration Res"},{"key":"2295_CR234","doi-asserted-by":"publisher","unstructured":"Li X, Wu B, Lu X, Yang J, Zhu Y, Yamagata HM, Han X (2026b) Lipid nanoparticle-mediated systemic RNA delivery to the spleen: strategies, applications, and challenges. ACS Nano Medicine https:\/\/doi.org\/10.1021\/acsnanomed.6c00043","DOI":"10.1021\/acsnanomed.6c00043"},{"key":"2295_CR239","doi-asserted-by":"crossref","unstructured":"Lim TR, Lim JG, Alibrahim Y, Punpichet M, Bharatha A, Beck ES, Suthiphosuwan S (2026) Conventional and emerging MRI biomarkers of multiple sclerosis. Radiographics, 46(3):e250069","DOI":"10.1148\/rg.250069"},{"issue":"\u2013 1","key":"2295_CR240","doi-asserted-by":"publisher","first-page":"100","DOI":"10.31138\/mjr.31.1.100","volume":"31","author":"CM Lin","year":"2020","unstructured":"Lin CM, Cooles FA, Isaacs JD (2020) Basic mechanisms of JAK inhibition. Mediterranean J Rheumatol 31(\u2013 1):100\u2013104","journal-title":"Mediterranean J Rheumatol"},{"key":"2295_CR241","doi-asserted-by":"publisher","unstructured":"Lin M, Zhang J, Zhang Y, Luo J, Shi S. Ocrelizumab for multiple sclerosis. Cochrane Database of Systematic Reviews 2022, Issue 5. Art. No.: CD013247. https:\/\/doi.org\/10.1002\/14651858.CD013247.pub2. Accessed 09 June 2026.","DOI":"10.1002\/14651858.CD013247.pub2"},{"issue":"8","key":"2295_CR242","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.3390\/ijms26083498","volume":"26","author":"C Liongue","year":"2025","unstructured":"Liongue C, Ward AC (2025) Cytokine receptor-like factor 3 (CRLF3) and its emerging roles in neurobiology, hematopoiesis and related human diseases. Int J Mol Sci 26(8):3498","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2295_CR243","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00204-024-03916-x","volume":"99","author":"H Liu","year":"2025","unstructured":"Liu H, Xu C, Hu Q, Wang Y (2025) Sepsis-induced cardiomyopathy: understanding pathophysiology and clinical implications. Arch Toxicol 99(2):467\u2013480","journal-title":"Arch Toxicol"},{"key":"2295_CR244","doi-asserted-by":"publisher","first-page":"S349","DOI":"10.1016\/S2152-2650(25)01525-3","volume":"25","author":"AC Logan","year":"2025","unstructured":"Logan AC, Shah BD, Pantin J, Jabbour E, Park JH, Shaughnessy P, Ngantung W (2025) ALL-357: an economic model comparing the costs associated with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) among patients treated with chimeric antigen receptor (CAR) T cell therapies for relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL). Clin Lymphoma Myeloma Leuk 25:S349","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2295_CR245","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Venkateshwara VR (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581\u2013590","journal-title":"Nat Med"},{"issue":"12","key":"2295_CR246","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.cmet.2025.09.008","volume":"37","author":"J Longo","year":"2025","unstructured":"Longo J, Watson MJ, Williams KS, Sheldon RD, Jones RG (2025) Nutrient allocation fuels T cell-mediated immunity. Cell Metabol 37(12):2311\u20132322","journal-title":"Cell Metabol"},{"key":"2295_CR247","doi-asserted-by":"crossref","unstructured":"Lontos K, Wang Y, Joshi SK, Frisch AT, Watson MJ, Kumar A, Lohmueller J (2023) Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors. J Immunother Cancer, 11(3):e006522","DOI":"10.1136\/jitc-2022-006522"},{"key":"2295_CR248","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Muguruza E, Peir\u00f3-Moreno C, Ruiz A, Matute C. Oligodendrocyte and Myelin Pathophysiology in Multiple Sclerosis. Adv Neurobiol. 2025;43:317-361. https:\/\/doi.org\/10.1007\/978-3-031-87919-7_12. PMID: 40500503.","DOI":"10.1007\/978-3-031-87919-7_12"},{"issue":"1","key":"2295_CR249","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31083\/JIN25081","volume":"24","author":"S Lorenzut","year":"2025","unstructured":"Lorenzut S, Negro ID, Pauletto G, Verriello L, Spadea L, Salati C, Zeppieri M (2025) Exploring the pathophysiology, diagnosis, and treatment options of multiple sclerosis. J Integr Neurosci 24(1):1\u201314","journal-title":"J Integr Neurosci"},{"issue":"11","key":"2295_CR250","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri.2016.93","volume":"16","author":"CL Lucas","year":"2016","unstructured":"Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K (2016) PI3K\u03b4 and primary immunodeficiencies. Nat Rev Immunol 16(11):702\u2013714","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2295_CR251","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41392-024-01934-w","volume":"9","author":"Y Lv","year":"2024","unstructured":"Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, Wang F (2024) The JAK-STAT pathway: from structural biology to cytokine engineering. Signal Transduct Target Therapy 9(1):221","journal-title":"Signal Transduct Target Therapy"},{"issue":"12","key":"2295_CR252","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1158\/2159-8290.CD-17-1084","volume":"7","author":"CL Mackall","year":"2017","unstructured":"Mackall CL, Miklos DB (2017) CNS endothelial cell activation emerges as a driver of CAR T cell\u2013associated neurotoxicity. Cancer Discov 7(12):1371\u20131373","journal-title":"Cancer Discov"},{"issue":"1","key":"2295_CR253","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-025-05251-2","volume":"176","author":"J Mahdi","year":"2026","unstructured":"Mahdi J, Gust JA, Vitanza NA, Scott B, Monje M, Ronsley R (2026) Neurotoxicity in central nervous system tumors treated with CAR T cell therapy: a review. J Neurooncol 176(1):1\u201310","journal-title":"J Neurooncol"},{"key":"2295_CR254","doi-asserted-by":"crossref","unstructured":"Mahmoudi F, McCarthy M, Nelson F (2025) Functional MRI and cognition in multiple sclerosis\u2014Where are we now? J Neuroimaging, 35(1), e13252","DOI":"10.1111\/jon.13252"},{"issue":"1","key":"2295_CR255","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112158","volume":"33","author":"B Malissen","year":"2015","unstructured":"Malissen B, Bongrand P (2015) Early T cell activation: integrating biochemical, structural, and biophysical cues. Annu Rev Immunol 33(1):539\u2013561","journal-title":"Annu Rev Immunol"},{"key":"2295_CR256","doi-asserted-by":"publisher","first-page":"102401","DOI":"10.1016\/j.jaut.2020.102401","volume":"108","author":"M Malviya","year":"2020","unstructured":"Malviya M, Saoudi A, Bauer J, Fillatreau S, Liblau R. Treatment of experimental autoimmune encephalomyelitis with engineered bi-specific Foxp3+ regulatory CD4+ T cells. J Autoimmun. 2020 Mar;108:102401. https:\/\/doi.org\/10.1016\/j.jaut.2020.102401. Epub 2020 Jan 13. PMID: 31948790.","journal-title":"J Autoimmun"},{"key":"2295_CR257","doi-asserted-by":"publisher","first-page":"103493","DOI":"10.1016\/j.msard.2022.103493","volume":"58","author":"HR Manglani","year":"2022","unstructured":"Manglani HR, Healy BC, Vranceanu A-M (2022) Demand with low supply: a pipeline for personalized integrative medicine in multiple sclerosis. Multiple Scler Relat Disorders 58:103493","journal-title":"Multiple Scler Relat disorders"},{"key":"2295_CR258","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","volume":"54","author":"S Manier","year":"2022","unstructured":"Manier S, Ingegnere T, Escure G, Prodhomme C, Nudel M, Mitra S, Facon T (2022) Current state and next-generation CAR-T cells in multiple myeloma. Blood Rev 54:100929","journal-title":"Blood Rev"},{"key":"2295_CR259","doi-asserted-by":"publisher","unstructured":"Marozzi MS, Desantis V, Corvasce F, Falcone GS, Santovito M, Colleoni G, Montagnani M, Vacca A, Cicco S. Impact of remote monitoring on well-being, therapeutic adherence, and organ damage evaluation in hypertensive patients: the PROSIT study. Eur Heart J Digit Health. 2026 Jan 6;7(2):ztag001. https:\/\/doi.org\/10.1093\/ehjdh\/ztag001. PMID: 41608669; PMCID: PMC12835817.","DOI":"10.1093\/ehjdh\/ztag001"},{"key":"2295_CR260","doi-asserted-by":"publisher","first-page":"640082","DOI":"10.3389\/fimmu.2021.640082","volume":"12","author":"D Mart\u00ednez Bedoya","year":"2021","unstructured":"Mart\u00ednez Bedoya D, Dutoit V, Migliorini D (2021) Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma. Front Immunol 12:640082","journal-title":"Front Immunol"},{"issue":"6","key":"2295_CR261","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1208\/s12248-025-01129-3","volume":"27","author":"M Masilamani","year":"2025","unstructured":"Masilamani M, Balasubramanian N, Mora J, Park A, Jawa V (2025) Cellular immunogenicity assessments in CAR-T cell therapies: current insights and future directions. AAPS J 27(6):140","journal-title":"AAPS J"},{"issue":"1","key":"2295_CR262","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1038\/s41598-025-94190-z","volume":"15","author":"N Massey","year":"2025","unstructured":"Massey N, Vasanthi SS, Gimenez-Lirola LG, Tyler H, Thippeswamy T (2025) Proinflammatory cytokines, oxidative stress, and organ function as biomarkers of soman (GD) chronic neurotoxicity. Sci Rep 15(1):9021","journal-title":"Sci Rep"},{"key":"2295_CR263","doi-asserted-by":"publisher","unstructured":"Mattei AE, Gutierrez AH, Seshadri S, Tivin J, Ardito M, Rosenberg AS, De Groot AS (2024) silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies. MAbs. 16(1):2333729. https:\/\/doi.org\/10.1080\/19420862.2024.2333729","DOI":"10.1080\/19420862.2024.2333729"},{"issue":"10","key":"2295_CR264","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.4049\/jimmunol.2200494","volume":"209","author":"AL Matter","year":"2022","unstructured":"Matter AL, Liggitt D, Goverman JM (2022) B cells drive MHC Class I\u2013Restricted CD4 T cells to induce spontaneous central nervous system autoimmunity. J Immunol 209(10):1880\u20131891","journal-title":"J Immunol"},{"issue":"16","key":"2295_CR265","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Lacey SF (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507\u20131517","journal-title":"N Engl J Med"},{"key":"2295_CR266","doi-asserted-by":"publisher","first-page":"102579","DOI":"10.1016\/j.coi.2025.102579","volume":"95","author":"E Maudes","year":"2025","unstructured":"Maudes E, Planagum\u00e0 J, Weber MS, Dalmau J (2025) Animal models of autoimmune encephalitis. Curr Opin Immunol 95:102579","journal-title":"Curr Opin Immunol"},{"issue":"15","key":"2295_CR267","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.3390\/ijms26157212","volume":"26","author":"MNH Maziz","year":"2025","unstructured":"Maziz MNH, Chakravarthi S, Aung T, Htoo PM, Shwe WH, Gupalo S, Thangarajan R (2025) Microglia-mediated neuroinflammation through phosphatidylinositol 3-kinase signaling causes cognitive dysfunction. Int J Mol Sci 26(15):7212","journal-title":"Int J Mol Sci"},{"issue":"14","key":"2295_CR268","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.3390\/ijms26146655","volume":"26","author":"AC Mazzeo","year":"2025","unstructured":"Mazzeo AC, Calabresi L, Damato V, Spagni G, Massacesi L, Mariottini A (2025) CD20\u2009+\u2009T cells in multiple sclerosis: from pathogenesis to treatment-induced depletion. Int J Mol Sci 26(14):6655","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2295_CR269","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD (2021) Diagnosis and treatment of multiple sclerosis: a review. JAMA 325(8):765\u2013779","journal-title":"JAMA"},{"key":"2295_CR270","doi-asserted-by":"crossref","unstructured":"Mendes O (2024) Inflammation and neurodegeneration in multiple sclerosis. A Review on Diverse Neurological Disorders. Elsevier, pp 321\u2013345","DOI":"10.1016\/B978-0-323-95735-9.00023-1"},{"issue":"11","key":"2295_CR271","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/jamaneurol.2018.2160","volume":"75","author":"JY Mescheriakova","year":"2018","unstructured":"Mescheriakova JY, Wong YYM, Runia TF, Jafari N, Samijn JP, de Beukelaar JW, Hintzen RQ (2018) Application of the 2017 revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome. JAMA Neurol 75(11):1392\u20131398","journal-title":"JAMA Neurol"},{"key":"2295_CR272","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fimmu.2015.00636","volume":"6","author":"L Michel","year":"2015","unstructured":"Michel L, Touil H, Pikor NB, Gommerman JL, Prat A, Bar-Or A. B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. Front Immunol. 2015 Dec 24;6:636. https:\/\/doi.org\/10.3389\/fimmu.2015.00636. PMID: 26732544; PMCID: PMC4689808.","journal-title":"Front Immunol"},{"key":"2295_CR273","doi-asserted-by":"crossref","unstructured":"Michels KR, Sheih A, Hernandez SA, Brandes AH, Parrilla D, Irwin B, Gervascio T (2023) Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J Immunother Cancer 11(3):e006292","DOI":"10.1136\/jitc-2022-006292"},{"issue":"11","key":"2295_CR274","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.15252\/emmm.201708148","volume":"9","author":"M Milani","year":"2017","unstructured":"Milani M, Annoni A, Bartolaccini S, Biffi M, Russo F, Di Tomaso T, Scheiflinger F (2017) Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy. EMBO Mol Med 9(11):1558\u20131573","journal-title":"EMBO Mol Med"},{"issue":"7","key":"2295_CR275","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U (2018) Clinical use of lentiviral vectors. Leukemia 32(7):1529\u20131541","journal-title":"Leukemia"},{"issue":"3","key":"2295_CR276","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41577-024-01093-7","volume":"25","author":"S Minguet","year":"2025","unstructured":"Minguet S, Maus MV, Schamel WW (2025) From TCR fundamental research to innovative chimeric antigen receptor design. Nat Rev Immunol 25(3):212\u2013224","journal-title":"Nat Rev Immunol"},{"key":"2295_CR277","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B (2023) From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol 14:1188049","journal-title":"Front Immunol"},{"issue":"6","key":"2295_CR278","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/brain\/awab093","volume":"144","author":"M Mitsdoerffer","year":"2021","unstructured":"Mitsdoerffer M, Di Liberto G, D\u00f6tsch S, Sie C, Wagner I, Pfaller M, Knier B (2021) Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity. Brain 144(6):1697\u20131710","journal-title":"Brain"},{"key":"2295_CR279","doi-asserted-by":"publisher","first-page":"991779","DOI":"10.3389\/fnins.2022.991779","volume":"16","author":"S Miyata","year":"2022","unstructured":"Miyata S (2022) Glial functions in the blood-brain communication at the circumventricular organs. Front NeuroSci 16:991779","journal-title":"Front NeuroSci"},{"key":"2295_CR280","doi-asserted-by":"publisher","unstructured":"Mohammadkhani N, Ebrahimi S, Hesam Mohammadi M, Hartmann TN, Poorebrahim M. Memory programming and new manufacturing paradigms in CAR-T cell therapy. Cancer Gene Ther. 2026 Mar 15. https:\/\/doi.org\/10.1038\/s41417-026-01015-w. Epub ahead of print. PMID: 41834019.","DOI":"10.1038\/s41417-026-01015-w"},{"issue":"4","key":"2295_CR281","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.rdc.2023.07.002","volume":"49","author":"S Mohan","year":"2023","unstructured":"Mohan S (2023) Targeted treatment of diseases of immune dysregulation. Rheumatic Disease Clin 49(4):913\u2013929","journal-title":"Rheumatic Disease Clin"},{"key":"2295_CR282","doi-asserted-by":"publisher","first-page":"1235222","DOI":"10.3389\/fimmu.2023.1235222","volume":"14","author":"CD Moorman","year":"2023","unstructured":"Moorman CD, Yu S, Briseno CG, Phee H, Sahoo A, Ramrakhiani A, Chaudhry A (2023) CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis. Front Immunol 14:1235222","journal-title":"Front Immunol"},{"issue":"8","key":"2295_CR283","doi-asserted-by":"publisher","first-page":"10182","DOI":"10.1007\/s12035-025-04903-8","volume":"62","author":"P Mosaddeghi","year":"2025","unstructured":"Mosaddeghi P, Mesbah-Namin SA, Javan M (2025) Evaluating the Protective effects of silymarin along with a cholesterol-supplemented diet against demyelination in an EAE mouse model of multiple sclerosis: lipidomic and inflammatory aspects. Mol Neurobiol 62(8):10182\u201310200","journal-title":"Mol Neurobiol"},{"issue":"10","key":"2295_CR284","doi-asserted-by":"publisher","first-page":"102647","DOI":"10.1016\/j.autrev.2020.102647","volume":"19","author":"T Moser","year":"2020","unstructured":"Moser T, Akg\u00fcn K, Proschmann U, Sellner J, Ziemssen T (2020) The role of TH17 cells in multiple sclerosis: therapeutic implications. Autoimmun Rev 19(10):102647","journal-title":"Autoimmun rev"},{"key":"2295_CR285","doi-asserted-by":"publisher","first-page":"103560","DOI":"10.1016\/j.msard.2022.103560","volume":"59","author":"T Moser","year":"2022","unstructured":"Moser T, Otto F, O\u2019Sullivan C, Hitzl W, Pilz G, Harrer A, Wipfler P (2022) Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications\u2013a pilot study. Multiple Scler Relat Disorders 59:103560","journal-title":"Multiple Scler Relat disorders"},{"issue":"1","key":"2295_CR286","doi-asserted-by":"publisher","first-page":"135","DOI":"10.17816\/brmma636850","volume":"27","author":"AV Moskalev","year":"2025","unstructured":"Moskalev AV, Gumilevskiy BY, Cygan BY, Apchel VY, Cygan VN (2025) T-cell receptor family, signal transduction, and transcription factors in T-cell immune response. Bull Russian Military Med Acad 27(1):135\u2013146","journal-title":"Bull Russian Military Med Acad"},{"issue":"1","key":"2295_CR287","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41392-024-01998-8","volume":"9","author":"D Mougiakakos","year":"2024","unstructured":"Mougiakakos D (2024) Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future. Signal Transduct Target Therapy 9(1):276","journal-title":"Signal Transduct Target Therapy"},{"key":"2295_CR288","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/B978-0-323-90887-0.00012-2","volume":"214","author":"D Mougiakakos","year":"2026","unstructured":"Mougiakakos D, Dalakas MC (2026) The future unfolded: CAR T cells and the transformation of treatment algorithms in autoimmune neurology. Handb Clin Neurol 214:439\u2013451","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"2295_CR289","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s42466-025-00379-y","volume":"7","author":"A Mrochen","year":"2025","unstructured":"Mrochen A, Meuth SG, Pfeuffer S (2025) Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis. Neurol Res Pract 7(1):25","journal-title":"Neurol Res Pract"},{"key":"2295_CR290","doi-asserted-by":"publisher","first-page":"639818","DOI":"10.3389\/fimmu.2021.639818","volume":"12","author":"YD Muller","year":"2021","unstructured":"Muller YD, Nguyen DP, Ferreira LM, Ho P, Raffin C, Valencia RVB, Van Gool F (2021) The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28. Front Immunol 12:639818","journal-title":"Front Immunol"},{"issue":"3","key":"2295_CR291","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41582-024-01050-x","volume":"21","author":"PA Muraro","year":"2025","unstructured":"Muraro PA, Mariottini A, Greco R, Burman J, Iacobaeus E, Inglese M, B\u00f8 L (2025) Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder\u2014recommendations from ECTRIMS and the EBMT. Nat Rev Neurol 21(3):140\u2013158","journal-title":"Nat Reviews Neurol"},{"key":"2295_CR292","doi-asserted-by":"crossref","unstructured":"Nandal K, Dahiya P, Kaur M, Jangra S. Therapeutic Modalities for Autoimmune Diseases: Current Challenges and Future Directions. InCutting-Edge Strategies in Drug Delivery and Immunotherapy for Autoimmune Disorders 2025 Oct 1 (pp. 163-189). Singapore: Springer Nature Singapore.","DOI":"10.1007\/978-981-95-0520-3_7"},{"key":"2295_CR293","doi-asserted-by":"crossref","unstructured":"Naveed M, Zhou Q-G, Han F (2019) Cerebrovascular inflammation: A critical trigger for neurovascular injury? Neurochemistry international. 126:165\u2013177","DOI":"10.1016\/j.neuint.2019.03.011"},{"key":"2295_CR294","doi-asserted-by":"publisher","unstructured":"Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igy\u00e1rt\u00f3 BZ. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021 Dec 17;24(12):103479. https:\/\/doi.org\/10.1016\/j.isci.2021.103479. Epub 2021 Nov 20. PMID: 34841223; PMCID: PMC8604799.","DOI":"10.1016\/j.isci.2021.103479"},{"issue":"9","key":"2295_CR295","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai CJ, Parker MH, Qin J, Tang W, Ulrich-Lewis JT, Gottschalk RJ, Mangio RS (2024) In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood 144(9):977\u2013987","journal-title":"Blood"},{"key":"2295_CR296","doi-asserted-by":"publisher","unstructured":"Nowicka Z, Zieli\u0144ska A, Koz\u0142owski M, Wasiak T, Stoczy\u0144ska-Fidelus E, Bogaczewicz A, et al. Extracorporeal blood purification in the management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a case report. Acta Haematologica Polonica. 2026 [Epub ahead of print May 5, 2026]. https:\/\/doi.org\/10.5603\/ahp.110710.","DOI":"10.5603\/ahp.110710"},{"key":"2295_CR297","doi-asserted-by":"publisher","unstructured":"Ohno R, Nakamura A. Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions. Semin Arthritis Rheum. 2024 Aug;67:152479. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152479. Epub 2024 May 24. PMID: 38810569.","DOI":"10.1016\/j.semarthrit.2024.152479"},{"issue":"1","key":"2295_CR298","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40120-017-0063-y","volume":"6","author":"M Okwuokenye","year":"2017","unstructured":"Okwuokenye M, Zhang A, Pace A, Peace KE (2017) Number needed to treat in multiple sclerosis clinical trials. Neurol Therapy 6(1):1\u20139","journal-title":"Neurol therapy"},{"issue":"1","key":"2295_CR299","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11481-025-10182-w","volume":"20","author":"JM Orian","year":"2025","unstructured":"Orian JM (2025) A new perspective on mechanisms of neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis: the early and critical role of platelets in neuro\/axonal loss. J Neuroimmune Pharmacol 20(1):14","journal-title":"J Neuroimmune Pharmacol"},{"key":"2295_CR300","doi-asserted-by":"crossref","unstructured":"Ortu\u00f1o-Sahag\u00fan D, Hermosillo-Abundis C, Reyes-Mata MP, Carri\u00f3n \u00d3A (2025) CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell\u2013driven neuroinflammation. Multiple sclerosis and related disorders, p 106812","DOI":"10.1016\/j.msard.2025.106812"},{"issue":"7","key":"2295_CR301","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11910-020-01045-3","volume":"20","author":"M Oset","year":"2020","unstructured":"Oset M, Stasiolek M, Matysiak M (2020) Cognitive dysfunction in the early stages of multiple sclerosis\u2014how much and how important? Curr Neurol Neurosci Rep 20(7):22","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"4","key":"2295_CR302","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40271-024-00695-6","volume":"18","author":"S Ozdemir","year":"2025","unstructured":"Ozdemir S, Quaife M, Mohamed AF, Norman R (2025) An overview of data collection in health preference research: S. Ozdemir et al. Patient-Patient-Centered Outcomes Res 18(4):303\u2013315","journal-title":"Patient-Patient-Centered Outcomes Res"},{"key":"2295_CR303","doi-asserted-by":"publisher","unstructured":"Ozguncu C, Ozturk S, Gumus H, Ozdemir G, Ozturk B, Guzel I, Ongun G. Investigation of the Relationship Between Serum Trace Elements and MSFC Levels in Multiple Sclerosis: A Cross-sectional Case-Control Study. Biol Trace Elem Res. 2025 Dec;203(12):6327-6336. https:\/\/doi.org\/10.1007\/s12011-025-04643-9. Epub 2025 May 5. PMID: 40323362; PMCID: PMC12672790.","DOI":"10.1007\/s12011-025-04643-9"},{"issue":"4","key":"2295_CR304","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","volume":"21","author":"A Page","year":"2024","unstructured":"Page A, Chuvin N, Valladeau-Guilemond J, Depil S (2024) Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol 21(4):315\u2013331","journal-title":"Cell Mol Immunol"},{"key":"2295_CR305","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Weissman D (2015) Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Controlled Release 217:345\u2013351","journal-title":"J Controlled Release"},{"issue":"1","key":"2295_CR306","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10238-025-01666-3","volume":"25","author":"DJ Park","year":"2025","unstructured":"Park DJ (2025) A unifying model for multiple sclerosis. Clin Exp Med 25(1):133","journal-title":"Clin Experimental Med"},{"issue":"5","key":"2295_CR307","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel KK, Tariveranmoshabad M, Kadu S, Shobaki N, June C (2025) From concept to cure: the evolution of CAR-T cell therapy. Mol Ther 33(5):2123\u20132140","journal-title":"Mol Ther"},{"key":"2295_CR308","doi-asserted-by":"publisher","unstructured":"Peck T (2025) Evaluating the mechanism of action of a novel heparan sulfate mimetic in an animal model of multiple sclerosis Open. Access Te Herenga Waka-Victoria University of Wellington] https:\/\/doi.org\/10.26686\/9R6G-MHDH","DOI":"10.26686\/9R6G-MHDH"},{"issue":"3","key":"2295_CR309","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/brain\/awae362","volume":"148","author":"LK Pfeffer","year":"2025","unstructured":"Pfeffer LK, Fischbach F, Heesen C, Friese MA (2025) Current state and perspectives of CAR T cell therapy in central nervous system diseases. Brain 148(3):723\u2013736","journal-title":"Brain"},{"issue":"11","key":"2295_CR310","doi-asserted-by":"publisher","first-page":"EMMM201809158","DOI":"10.15252\/emmm.201809158","volume":"10","author":"A Pfeiffer","year":"2018","unstructured":"Pfeiffer A, Thalheimer FB, Hartmann S, Frank AM, Bender RR, Danisch S, Stripecke R (2018) In vivo generation of human CD19-CAR T cells results in B\u2010cell depletion and signs of cytokine release syndrome. EMBO Mol Med 10(11):EMMM201809158","journal-title":"EMBO Mol Med"},{"key":"2295_CR311","doi-asserted-by":"publisher","first-page":"104222","DOI":"10.1016\/j.cellimm.2020.104222","volume":"358","author":"ADP Pohl","year":"2020","unstructured":"Pohl ADP, Schmidt A, Zhang A-H, Maldonado T, K\u00f6nigs C, Scott DW (2020) Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression. Cell Immunol 358:104222","journal-title":"Cell Immunol"},{"issue":"6","key":"2295_CR312","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/JLB.2MIR0817-349R","volume":"103","author":"SL Pompura","year":"2018","unstructured":"Pompura SL, Dominguez-Villar M (2018) The PI3K\/AKT signaling pathway in regulatory T-cell development, stability, and function. J Leukoc Biol 103(6):1065\u20131076","journal-title":"J Leukoc Biol"},{"key":"2295_CR313","doi-asserted-by":"publisher","unstructured":"Hosseini Rad A, Min Yi Tan G, Poudel A, McLellan A. P06.02\u2005Enhancing CAR T cell persistence and memory through modulating mitochondrial function. Journal for ImmunoTherapy of Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-ITOC7.81","DOI":"10.1136\/jitc-2020-ITOC7.81"},{"issue":"3","key":"2295_CR314","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17(3):147\u2013167","journal-title":"Nat reviews Clin Oncol"},{"key":"2295_CR315","doi-asserted-by":"crossref","unstructured":"Rajabi M, Shafaeibajestan S, Asadpour S, Alyari G, Taei N, Kohkalani M, Saburi E (2025) Primary progressive multiple sclerosis: new therapeutic approaches. Neuropsychopharmacol Rep, 45(3), e70039","DOI":"10.1002\/npr2.70039"},{"issue":"6","key":"2295_CR316","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41587-024-02339-4","volume":"43","author":"T Rakhshandehroo","year":"2025","unstructured":"Rakhshandehroo T, Mantri SR, Moravej H, Louis BB, Salehi Farid A, Munaretto L, Farkash Z (2025) A CAR enhancer increases the activity and persistence of CAR T cells. Nat Biotechnol 43(6):948\u2013959","journal-title":"Nat Biotechnol"},{"key":"2295_CR317","first-page":"1","volume-title":"Test\u2013retest reliability of cognitive fatigability measures during the SDMT and PASAT in people with multiple sclerosis","author":"C Ramari","year":"2025","unstructured":"Ramari C, Abasiyanik Z, Balistieri Santinelli F, D\u2019hooge M, Triccas T, Lamers L, Feys I, P (2025) Test\u2013retest reliability of cognitive fatigability measures during the SDMT and PASAT in people with multiple sclerosis. Biomed Health Behav Fatigue, pp 1\u20139"},{"issue":"14","key":"2295_CR318","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1182\/blood.2023022922","volume":"145","author":"A Rampotas","year":"2025","unstructured":"Rampotas A, Roddie C (2025) The present and future of CAR T-cell therapy for adult B-cell ALL. Blood 145(14):1485\u20131497","journal-title":"Blood"},{"issue":"6","key":"2295_CR319","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.medj.2024.04.005","volume":"5","author":"AW Rankin","year":"2024","unstructured":"Rankin AW, Shah NN (2024) CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier. Med 5(6):482\u2013484","journal-title":"Med"},{"key":"2295_CR320","doi-asserted-by":"publisher","unstructured":"Rao SM, Sokolowski M, Strober LB, Miller JB, Norman MA, Levitt N, Williams JR, de Moor C. Multiple Sclerosis Performance Test (MSPT): Normative study of 428 healthy participants ages 18 to 89. Mult Scler Relat Disord. 2022 Mar;59:103644. https:\/\/doi.org\/10.1016\/j.msard.2022.103644. Epub 2022 Jan 30. PMID: 35182881.","DOI":"10.1016\/j.msard.2022.103644"},{"issue":"10","key":"2295_CR321","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1111\/sms.14407","volume":"33","author":"S Reina-Guti\u00e9rrez","year":"2023","unstructured":"Reina-Guti\u00e9rrez S, Meseguer\u2010Henarejos AB, Torres\u2010Costoso A, \u00c1lvarez\u2010Bueno C, Cavero\u2010Redondo I, de N\u00fa\u00f1ez S, Mart\u00ednez\u2010Vizca\u00edno V (2023) Effect of different types of exercise on fitness in people with multiple sclerosis: a network meta\u2010analysis. Scand J Med Sci Sports 33(10):1916\u20131928","journal-title":"Scand J Med Sci Sports"},{"issue":"7","key":"2295_CR322","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1182\/blood.2025028833","volume":"146","author":"K Rejeski","year":"2025","unstructured":"Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, Einarsdottir S (2025) T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood 146(7):834\u2013846","journal-title":"Blood"},{"issue":"1","key":"2295_CR323","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11011-026-01837-5","volume":"41","author":"V RN","year":"2026","unstructured":"RN V (2026) Animal models of multiple sclerosis: applications and future directions in disease research. Metab Brain Dis 41(1):67","journal-title":"Metab Brain Dis"},{"key":"2295_CR324","doi-asserted-by":"publisher","unstructured":"Rocca MA, Preziosa P, Filippi M. Progressive multiple sclerosis: Six trials to watch. Med. 2026 Jan 9;7(1):100960. https:\/\/doi.org\/10.1016\/j.medj.2025.100960. PMID: 41519116.","DOI":"10.1016\/j.medj.2025.100960"},{"issue":"30","key":"2295_CR325","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.21.00917","volume":"39","author":"C Roddie","year":"2021","unstructured":"Roddie C, Dias J, O\u2019Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, Roddy H (2021) Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. J Clin Oncol 39(30):3352\u20133363","journal-title":"J Clin Oncol"},{"issue":"4","key":"2295_CR326","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/brain\/awab385","volume":"145","author":"J Rodgers","year":"2022","unstructured":"Rodgers J, Friede T, Vonberg FW, Constantinescu CS, Coles A, Chataway J, Fisniku L (2022) The impact of smoking cessation on multiple sclerosis disease progression. Brain 145(4):1368\u20131378","journal-title":"Brain"},{"issue":"1","key":"2295_CR327","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40364-025-00783-1","volume":"13","author":"S Saeidpour Masouleh","year":"2025","unstructured":"Saeidpour Masouleh S, Nasiri K, Ostovar Ravari A, Saligheh Rad M, Kiani K, Sharifi Sultani A, Nabi Afjadi M (2025) Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma. Biomark Res 13(1):69","journal-title":"Biomark Res"},{"key":"2295_CR328","doi-asserted-by":"crossref","unstructured":"Sahlolbei M, Azangou-Khyavy M, Khanali J, Khorsand B, Shiralipour A, Ahmadbeigi N, Hashemi SM (2023) Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: an in-vitro study. Heliyon, 9(9)","DOI":"10.1016\/j.heliyon.2023.e19763"},{"issue":"5","key":"2295_CR329","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s10072-022-06582-y","volume":"44","author":"S Saidha","year":"2023","unstructured":"Saidha S, Bell J, Harold S, Belisario JM, Hawe E, Shao Q, Maiese EM (2023) Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis. Neurol Sci 44(5):1515\u20131532","journal-title":"Neurol Sci"},{"key":"2295_CR330","doi-asserted-by":"crossref","unstructured":"Salame H, Jaber R, Taher H, Olleik M, Farhat A, Khouri L (2026) Allgrove syndrome with early neurodegeneration in a child: a case report from Syria. Medicine, 105(3), e47238","DOI":"10.1097\/MD.0000000000047238"},{"key":"2295_CR331","doi-asserted-by":"publisher","unstructured":"Samadzadeh S, Szejko N, Hamadah Y, Tan WY, Gluscevic S, Boldrini V, Ricigliano VAG, Hartung HP, Montalban X; ECF Young Investigators\/Fellows Initiative. CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders. J Neuroinflammation. 2025 Dec 30;23(1):35. https:\/\/doi.org\/10.1186\/s12974-025-03668-0. PMID: 41470000; PMCID: PMC12837059.","DOI":"10.1186\/s12974-025-03668-0"},{"issue":"1","key":"2295_CR332","doi-asserted-by":"publisher","first-page":"249","DOI":"10.21873\/anticanres.17939","volume":"46","author":"D Samutpradit","year":"2026","unstructured":"Samutpradit D, Areesawangkit P, Hengswat P, Chiraphapphaiboon W, Phikulsod P, Choome K, Sukpanichnant S (2026) Self-differentiated dendritic cells presenting NY-ESO-1 prime cytotoxic T cells for the treatment of multiple myeloma. Anticancer Res 46(1):249\u2013262","journal-title":"Anticancer Res"},{"key":"2295_CR333","doi-asserted-by":"publisher","first-page":"1055466","DOI":"10.3389\/fimmu.2022.1055466","volume":"13","author":"JM Sanders","year":"2022","unstructured":"Sanders JM, Jeyamogan S, Mathew JM, Leventhal JR (2022) Foxp3\u2009+\u2009regulatory T cell therapy for tolerance in autoimmunity and solid organ transplantation. Front Immunol 13:1055466","journal-title":"Front Immunol"},{"key":"2295_CR334","doi-asserted-by":"crossref","unstructured":"Santani BG, Mishra AK, Thakare R (2025) CAR T-cell therapy-associated toxicities. cell-based immunotherapies for cancer. Springer, pp 203\u2013233","DOI":"10.1007\/978-3-031-88695-9_8"},{"issue":"20","key":"2295_CR335","first-page":"2443","volume":"141","author":"BD Santomasso","year":"2023","unstructured":"Santomasso BD, Gust J, Perna F (2023) How I treat unique and difficult-to-manage cases of CAR T-cell therapy\u2013associated neurotoxicity. Blood J Am Soc Hematol 141(20):2443\u20132451","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"2295_CR336","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","volume":"7","author":"M Scherlinger","year":"2025","unstructured":"Scherlinger M, Nocturne G, Radic M, Launay D, Richez C, Bousso P, Bigenwald C (2025) CAR T-cell therapy in autoimmune diseases: where are we and where are we going? Lancet Rheumatol 7(6):e434\u2013e447","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"2295_CR337","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jth.14322","volume":"17","author":"M Schillemans","year":"2019","unstructured":"Schillemans M, Karampini E, Kat M, Bierings R (2019) Exocytosis of Weibel\u2013Palade bodies: how to unpack a vascular emergency kit. J Thromb Haemost 17(1):6\u201318","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2295_CR338","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00134-024-07576-4","volume":"50","author":"T Schroeder","year":"2024","unstructured":"Schroeder T, Martens T, Fransecky L, Valerius T, Schub N, Pott C, St\u00f6lzel F (2024) Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities. Intensive Care Med 50(9):1459\u20131469","journal-title":"Intensive Care Med"},{"issue":"9","key":"2295_CR339","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1038\/s41596-025-01169-1","volume":"20","author":"JM Sealock","year":"2025","unstructured":"Sealock JM, Ivankovic F, Liao C, Chen S, Churchhouse C, Karczewski KJ, Neale BM (2025) Tutorial: guidelines for quality filtering of whole-exome and whole-genome sequencing data for population-scale association analyses. Nat Protoc 20(9):2372\u20132382","journal-title":"Nat Protoc"},{"key":"2295_CR340","doi-asserted-by":"publisher","first-page":"34693461","DOI":"10.1182\/blood-2024-204169","volume":"144","author":"MR Seshadri","year":"2024","unstructured":"Seshadri MR, Gupta S, Lincoln R, Okinishi N, Thomas N, Wilmoth J, Cree BA (2024) A Study of Kyv-101, a CD19 CAR T Cell Therapy, in Participants with Treatment Refractory Progressive Multiple Sclerosis. Blood 144:34693461","journal-title":"Blood"},{"issue":"1","key":"2295_CR341","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12035-025-05348-9","volume":"63","author":"VK Sharma","year":"2026","unstructured":"Sharma VK (2026) Microbiota-derived SCFAs in multiple sclerosis: from immune priming to neurodegeneration. Mol Neurobiol 63(1):1\u201321","journal-title":"Mol Neurobiol"},{"key":"2295_CR342","doi-asserted-by":"crossref","unstructured":"Sherman LS, Wall JD, Wong SW (2026) Nonhuman primate models of multiple sclerosis: advantages over rodent models for preclinical studies. Animal Models of Neurological Conditions. Elsevier, pp 415\u2013429","DOI":"10.1016\/B978-0-443-29090-9.00007-6"},{"issue":"7","key":"2295_CR343","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jtct.2025.03.011","volume":"31","author":"R Shouval","year":"2025","unstructured":"Shouval R, Strouse C, Kim S, Oloyede T, Ahmed S, Awan FT, Bar M (2025) Cytokine release syndrome and neurotoxicity following CD19 CAR-T in B-cell lymphoma. Transplantation Cell therapy 31(7):419\u2013433","journal-title":"Transplantation Cell therapy"},{"issue":"9","key":"2295_CR346","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1084\/jem.20171820","volume":"215","author":"MD Singh","year":"2018","unstructured":"Singh MD, Ni M, Sullivan JM, Hamerman JA, Campbell DJ (2018) B cell adaptor for PI3-kinase (BCAP) modulates CD8\u2009+\u2009effector and memory T cell differentiation. J Exp Med 215(9):2429\u20132443","journal-title":"J Exp Med"},{"issue":"4","key":"2295_CR344","doi-asserted-by":"publisher","first-page":"100139","DOI":"10.1016\/j.phyplu.2021.100139","volume":"1","author":"A Singh","year":"2021","unstructured":"Singh A, Upadhayay S, Mehan S (2021a) Inhibition of c-JNK\/p38MAPK signaling pathway by Apigenin prevents neurobehavioral and neurochemical defects in ethidium bromide-induced experimental model of multiple sclerosis in rats: Evidence from CSF, blood plasma and brain samples. Phytomedicine plus 1(4):100139","journal-title":"Phytomedicine plus"},{"issue":"5","key":"2295_CR345","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1007\/s12640-021-00401-6","volume":"39","author":"A Singh","year":"2021","unstructured":"Singh A, Upadhayay S, Mehan S (2021b) Understanding abnormal c-JNK\/p38MAPK signaling overactivation involved in the progression of multiple sclerosis: possible therapeutic targets and impact on neurodegenerative diseases. Neurotox Res 39(5):1630\u20131650","journal-title":"Neurotox Res"},{"issue":"19","key":"2295_CR347","doi-asserted-by":"publisher","first-page":"9398","DOI":"10.3390\/ijms26199398","volume":"26","author":"C Skarlis","year":"2025","unstructured":"Skarlis C, Angelopoulou E, Rentzos M, Papageorgiou SG, Anagnostouli M (2025) Monoclonal antibodies as therapeutic agents in autoimmune and neurodegenerative diseases of the central nervous system: current evidence on molecular mechanisms and future directions. Int J Mol Sci 26(19):9398","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2295_CR348","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, Stephan MT (2017) In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol 12(8):813\u2013820","journal-title":"Nat Nanotechnol"},{"issue":"5","key":"2295_CR349","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/1873-3468.15053","volume":"599","author":"Y Soliman","year":"2025","unstructured":"Soliman Y, Al-khodor J, Yildirim K\u00f6ken G, Mustafaoglu N (2025) A guide for blood\u2013brain barrier models. FEBS Lett 599(5):599\u2013644","journal-title":"FEBS Lett"},{"issue":"1","key":"2295_CR350","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","volume":"9","author":"Y Song","year":"2024","unstructured":"Song Y, Li J, Wu Y (2024) Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. Signal Transduct Target Therapy 9(1):263","journal-title":"Signal Transduct Target Therapy"},{"key":"2295_CR351","doi-asserted-by":"crossref","unstructured":"Speth K, Xie J, Song Q, Mattie M, Kim JJ, Barrett DM, Adhikary S (2025) Classification of patients with relapsed\/refractory large B-cell lymphoma who do not develop early CRS\/NE toxicity using ZUMA clinical trial data. J Immunother Cancer, 13(8), e011819","DOI":"10.1136\/jitc-2025-011819"},{"key":"2295_CR352","doi-asserted-by":"publisher","first-page":"175628642513216","DOI":"10.1177\/17562864251321669","volume":"18","author":"M-I Stefanou","year":"2025","unstructured":"Stefanou M-I, Theodorou A, Mengel A, Melanis K, Bakirtzis C, Giannopapas V, Tzanetakos D (2025) Risk of stroke under disease modifying therapies for multiple sclerosis: a systematic review. Ther Adv Neurol Disord 18:17562864251321669","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"2295_CR353","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","volume":"21","author":"M Stockfelt","year":"2025","unstructured":"Stockfelt M, Teng YO, Vital EM (2025) Opportunities and limitations of B cell depletion approaches in SLE. Nat Rev Rheumatol 21(2):111\u2013126","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"2295_CR354","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/17512433.2025.2481868","volume":"18","author":"L Strasser","year":"2025","unstructured":"Strasser L, Ciftci B, Johnstone J, Cunningham J, Tremlett H, Yeh EA (2025) Scoping review of the availability and uptake of disease modifying therapies in children and adolescents with multiple sclerosis. Expert Rev Clin Pharmacol 18(4):197\u2013210","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2295_CR355","doi-asserted-by":"crossref","unstructured":"Strati P, Leslie L, Shiraz P, Budde LE, Oluwole OO, Ulrickson M, Milletti F (2026) Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial. Nat Cancer, 1\u201312","DOI":"10.1038\/s43018-025-01102-1"},{"key":"2295_CR356","doi-asserted-by":"publisher","first-page":"104751","DOI":"10.1016\/j.critrevonc.2025.104751","volume":"211","author":"A Suchiita","year":"2025","unstructured":"Suchiita A, Sonkar SC (2025) Revolutionizing immunotherapy: the next frontier in CAR T-cell engineering. Crit Rev Oncol\/Hematol 211:104751","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"3","key":"2295_CR357","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40120-025-00728-8","volume":"14","author":"AB Sullivan","year":"2025","unstructured":"Sullivan AB, Davis B, Kidd J, Chiong-Rivero H (2025) Understanding depression in people living with multiple sclerosis: a narrative review of recent literature. Neurol Therapy 14(3):681\u2013710","journal-title":"Neurol therapy"},{"key":"2295_CR358","doi-asserted-by":"publisher","unstructured":"Sun J, Chen M. Navigating AKT-ivity across cellular compartments. Trends Cell Biol. 2026 Feb;36(2):125-141. https:\/\/doi.org\/10.1016\/j.tcb.2025.08.001. Epub 2025 Aug 28. PMID: 40883141.","DOI":"10.1016\/j.tcb.2025.08.001"},{"key":"2295_CR359","doi-asserted-by":"publisher","first-page":"113779","DOI":"10.1016\/j.intimp.2024.113779","volume":"145","author":"Y Sun","year":"2025","unstructured":"Sun Y, Huang S, Zhang B, Peng Y, Lu H, Jia Y, Peng L (2025) Efficacy and safety of anti-CD19 CAR-T in a mouse model of IgG4-related disease. Int Immunopharmacol 145:113779","journal-title":"Int Immunopharmacol"},{"key":"2295_CR360","doi-asserted-by":"crossref","unstructured":"Synnott D, O\u2019Reilly D, De Freitas D, Naidoo J (2025) Cytokine release syndrome in solid tumors. Cancer, 131(17), e70069","DOI":"10.1002\/cncr.70069"},{"issue":"1","key":"2295_CR361","doi-asserted-by":"publisher","first-page":"241052","DOI":"10.1098\/rsos.241052","volume":"12","author":"AC Szekely-Kohn","year":"2025","unstructured":"Szekely-Kohn AC, Castellani M, Espino DM, Baronti L, Ahmed Z, Manifold WG, Douglas M (2025) Machine learning for refining interpretation of magnetic resonance imaging scans in the management of multiple sclerosis: a narrative review. Royal Soc open Sci 12(1):241052","journal-title":"Royal Soc open Sci"},{"issue":"3","key":"2295_CR362","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.immuni.2017.02.010","volume":"46","author":"H Tan","year":"2017","unstructured":"Tan H, Yang K, Li Y, Shaw TI, Wang Y, Blanco DB, Rankin S (2017) Integrative proteomics and phosphoproteomics profiling reveals dynamic signaling networks and bioenergetics pathways underlying T cell activation. Immunity 46(3):488\u2013503","journal-title":"Immunity"},{"key":"2295_CR363","doi-asserted-by":"publisher","first-page":"1675251","DOI":"10.3389\/fimmu.2025.1675251","volume":"16","author":"ES Tay","year":"2025","unstructured":"Tay ES, Ting YT, Gan P-Y, Ooi JD (2025) Regulatory T cell therapy for myeloperoxidase-specific anti-neutrophil cytoplasmic antibody associated vasculitis. Front Immunol 16:1675251","journal-title":"Front Immunol"},{"issue":"1","key":"2295_CR364","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1080\/16078454.2021.1965725","volume":"26","author":"A Theyab","year":"2021","unstructured":"Theyab A, Algahtani M, Alsharif KF, Hawsawi YM, Alghamdi A, Alghamdi A, Akinwale J (2021) New insight into the mechanism of granulocyte colony-stimulating factor (G-CSF) that induces the mobilization of neutrophils. Hematology 26(1):628\u2013636","journal-title":"Hematology"},{"key":"2295_CR365","doi-asserted-by":"crossref","unstructured":"Thirugnanam A, Donthineni K, Mammi M, Hundel J, Munteh D, D\u2019Amore F, Mekary RA (2025) Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: a meta-analysis. Crit Rev Oncol\/Hematol, 105095.","DOI":"10.1016\/j.critrevonc.2025.105095"},{"issue":"2","key":"2295_CR366","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Freedman MS (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"issue":"23","key":"2295_CR367","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1182\/bloodadvances.2020003844","volume":"5","author":"K Thudium Mueller","year":"2021","unstructured":"Thudium Mueller K, Grupp SA, Maude SL, Levine JE, Pulsipher MA, Boyer MW, Jaeger U (2021) Tisagenlecleucel immunogenicity in relapsed\/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Adv 5(23):4980\u20134991","journal-title":"Blood Adv"},{"issue":"1","key":"2295_CR368","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S (2019) Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer 120(1):26\u201337","journal-title":"Br J Cancer"},{"key":"2295_CR369","doi-asserted-by":"publisher","unstructured":"Topka M, Schneider M, Zrenner C, Belardinelli P, Ziemann U, Weiss D (2022) Motor cortex excitability is reduced during freezing of upper limb movement in Parkinson\u2019s disease. NPJ Parkinson\u2019s disease 8(1):161. https:\/\/doi.org\/10.1038\/s41531-022-00420-w","DOI":"10.1038\/s41531-022-00420-w"},{"key":"2295_CR370","doi-asserted-by":"crossref","unstructured":"Trehan M, Sengupta A, Sharma H, Dass J, Kumar P, Yadav S, Aggarwal M. Imatinib-Induced Cardiac Tamponade in a Chronic Phase CML Patient: A Rare and Reversible Complication. Indian Journal of Hematology and Blood Transfusion. 2026 Jan 10:1-3.","DOI":"10.1007\/s12288-025-02297-0"},{"issue":"1","key":"2295_CR371","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00068-024-02726-1","volume":"51","author":"H Trentzsch","year":"2025","unstructured":"Trentzsch H, Goossen K, Prediger B, Schweigkofler U, Hilbert-Carius P, Hanken H, Hinck D (2025) Stop the bleed \u2013Prehospital bleeding control in patients with multiple and\/or severe injuries\u2013A systematic review and clinical practice guideline\u2013A systematic review and clinical practice guideline. Eur J Trauma Emerg Surg 51(1):92","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"1","key":"2295_CR372","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-022-00593-1","volume":"18","author":"E Udine","year":"2023","unstructured":"Udine E, Jain A, van Blitterswijk M (2023) Advances in sequencing technologies for amyotrophic lateral sclerosis research. Mol neurodegeneration 18(1):4","journal-title":"Mol neurodegeneration"},{"key":"2295_CR373","doi-asserted-by":"crossref","unstructured":"Uher T (2025) Clinical red flags and key features in the differential diagnosis of multiple sclerosis. Mimics and Red Flags of Multiple Sclerosis. Springer, pp 583\u2013609","DOI":"10.1007\/978-3-031-98945-2_13"},{"key":"2295_CR374","doi-asserted-by":"publisher","first-page":"100019","DOI":"10.1016\/j.dscb.2021.100019","volume":"3","author":"S Upadhayay","year":"2021","unstructured":"Upadhayay S, Mehan S (2021) Targeting Nrf2\/HO-1 anti-oxidant signaling pathway in the progression of multiple sclerosis and influences on neurological dysfunctions. Brain Disorders 3:100019","journal-title":"Brain Disorders"},{"issue":"11","key":"2295_CR375","doi-asserted-by":"publisher","first-page":"14367","DOI":"10.1007\/s12035-025-04962-x","volume":"62","author":"S Upadhayay","year":"2025","unstructured":"Upadhayay S, Soni D, Dhureja M, Temgire P, Kumar V, Arthur R, Kumar P (2025) Role of fibroblast growth factors in neurological disorders: insight into therapeutic approaches and molecular mechanisms. Mol Neurobiol 62(11):14367\u201314386","journal-title":"Mol Neurobiol"},{"issue":"1","key":"2295_CR376","first-page":"44","volume":"134","author":"JA van Bruggen","year":"2019","unstructured":"van Bruggen JA, Martens AW, Fraietta JA, Hofland T, Tonino SH, Eldering E, Rathmell JC (2019) Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8\u2009+\u2009T cells and impede CAR T-cell efficacy. Blood J Am Soc Hematol 134(1):44\u201358","journal-title":"Blood J Am Soc Hematol"},{"key":"2295_CR377","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3389\/fimmu.2020.00760","volume":"11","author":"J Van Langelaar","year":"2020","unstructured":"Van Langelaar J, Rijvers L, Smolders J, Van Luijn MM (2020) B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers. Front Immunol 11:760","journal-title":"Front Immunol"},{"key":"2295_CR378","doi-asserted-by":"crossref","unstructured":"Vasil N, Razzaque MS (2025) Decoding vitamin D intake: How much is too much? Vitamin D function: from mineral ion regulation to infection. Springer, pp 5\u201312","DOI":"10.1007\/978-3-032-04357-3_2"},{"issue":"3","key":"2295_CR379","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40120-025-00726-w","volume":"14","author":"P Vermersch","year":"2025","unstructured":"Vermersch P, Moisset X, Roux B, Lecomte A, Luciani L, Paret M, de S\u00e8ze J (2025) Long-term management and therapeutic sequencing for patients with relapsing multiple sclerosis in France: a vignette study. Neurol Therapy 14(3):813\u2013827","journal-title":"Neurol therapy"},{"key":"2295_CR380","doi-asserted-by":"publisher","first-page":"1657738","DOI":"10.3389\/fimmu.2025.1657738","volume":"16","author":"S Vicente-Gil","year":"2025","unstructured":"Vicente-Gil S, Pianese V, Morel E, Ab\u00f3s B, Jim\u00e9nez-Barrios P, Perdiguero P, Scapigliati G (2025) IgT and IgD dominance in the teleost central nervous system. Front Immunol 16:1657738","journal-title":"Front Immunol"},{"key":"2295_CR381","doi-asserted-by":"crossref","unstructured":"Vichare A, Lee JS, Duong TQ (2025) Neuroimaging findings of CAR T-cell-associated neurotoxicity: a review. Neurology: Clin Pract, 15(4), e200488","DOI":"10.1212\/CPJ.0000000000200488"},{"issue":"12","key":"2295_CR382","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","volume":"5","author":"A Vijenthira","year":"2021","unstructured":"Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK (2021) Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv 5(12):2624\u20132643","journal-title":"Blood Adv"},{"issue":"3","key":"2295_CR383","doi-asserted-by":"publisher","first-page":"4","DOI":"10.32607\/actanaturae.27728","volume":"17","author":"D Volkov","year":"2025","unstructured":"Volkov D, Stepanova V, Yaroshevich I, Gabibov A, Rubtsov Y (2025) The impact of the intracellular domains of chimeric antigenic receptors on the properties of CAR T-cells. Acta Naturae 17(3):4","journal-title":"Acta Naturae"},{"key":"2295_CR384","doi-asserted-by":"crossref","unstructured":"Wafa M, Giovannoni G (2026) Lost in space, lost in time: a clinician\u2019s proposed approach to the diagnosis of multiple sclerosis. Multiple Sclerosis and Related Disorders, p 106989","DOI":"10.1016\/j.msard.2026.106989"},{"issue":"9Supplement2","key":"2295_CR385","first-page":"S74","volume":"87","author":"A Waldman","year":"2016","unstructured":"Waldman A, Ness J, Pohl D, Simone IL, Anlar B, Amato MP, Ghezzi A (2016) Pediatric multiple sclerosis: clinical features and outcome. Neurology 87(9Supplement2):S74\u2013S81","journal-title":"Neurology"},{"issue":"1","key":"2295_CR386","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.emc.2025.08.002","volume":"44","author":"S Walton","year":"2026","unstructured":"Walton S, Gottlieb M, Long B (2026) The emergency department-focused neurologic examination. Emerg Med Clin 44(1):1\u201319","journal-title":"Emerg Med Clin"},{"issue":"4","key":"2295_CR387","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/BS9.0000000000000173","volume":"5","author":"J-Y Wang","year":"2023","unstructured":"Wang J-Y, Wang L (2023) CAR-T cell therapy: where are we now, and where are we heading? Blood Sci 5(4):237\u2013248","journal-title":"Blood Sci"},{"issue":"1","key":"2295_CR390","doi-asserted-by":"publisher","first-page":"103488","DOI":"10.1016\/j.retram.2024.103488","volume":"73","author":"Z Wang","year":"2025","unstructured":"Wang Z, Zhang G (2025) CAR-iNKT cell therapy: mechanisms, advantages, and challenges. Curr Res Translational Med 73(1):103488","journal-title":"Curr Res Translational Med"},{"issue":"1","key":"2295_CR388","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Liu Y, He Z, Li L, Liu S, Jiang M, Mi X (2024) Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discovery 10(1):40","journal-title":"Cell death discovery"},{"key":"2295_CR389","unstructured":"Wang X, Wen B, Duan X, Zhang Y, Hu Y, Li H, Jing Y (2025) Recent advances of type I interferon on the regulation of immune cells and the treatment of systemic lupus erythematosus. J Inflamm Res, 4533\u20134549"},{"key":"2295_CR391","doi-asserted-by":"crossref","unstructured":"Watt J, Hodson T, Di Tommaso A (2025) Experiences and perspectives of Australian occupational therapists on environmental sustainability: a qualitative study. Aust Occup Ther J, 72(5), e70052","DOI":"10.1111\/1440-1630.70052"},{"issue":"1","key":"2295_CR392","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/bloodadvances.2025018076","volume":"10","author":"R Weinkove","year":"2026","unstructured":"Weinkove R, Jarvis E-M (2026) Blood tests to predict CAR T-cell toxicity and efficacy. Blood Adv 10(1):273\u2013275","journal-title":"Blood Adv"},{"issue":"8","key":"2295_CR393","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/1352458516643394","volume":"22","author":"H Westerlind","year":"2016","unstructured":"Westerlind H, Stawiarz L, Fink K, Hillert J, Manouchehrinia A (2016) A significant decrease in diagnosis of primary progressive multiple sclerosis: a cohort study. Multiple Scler J 22(8):1071\u20131079","journal-title":"Multiple Scler J"},{"issue":"1","key":"2295_CR394","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12955-022-02046-1","volume":"20","author":"OC Wills","year":"2022","unstructured":"Wills OC, Probst YC (2022) Understanding lifestyle self-management regimens that improve the life quality of people living with multiple sclerosis: a systematic review and meta-analysis. Health Qual Life Outcomes 20(1):153","journal-title":"Health Qual Life Outcomes"},{"key":"2295_CR395","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fmed.2020.00303","volume":"7","author":"LM Wise","year":"2020","unstructured":"Wise LM, Stohl W (2020) Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents. Front Med 7:303","journal-title":"Front Med"},{"key":"2295_CR396","doi-asserted-by":"publisher","first-page":"1631557","DOI":"10.3389\/fonc.2025.1631557","volume":"15","author":"H Wobma","year":"2025","unstructured":"Wobma H, Henderson LA, Duncan CN, Prockop SE, Randolph AG, Degar BA, Baumeister SH (2025) Treating and triggering hyperinflammation: tackling hemophagocytic lymphohistiocytosis and HLH-like syndromes in the pediatric cell therapy and critical care setting. Front Oncol 15:1631557","journal-title":"Front Oncol"},{"key":"2295_CR397","doi-asserted-by":"crossref","unstructured":"Wosiski-Kuhn M, Lullmann O, Luo Y (2025) Sonic hedgehog signaling: linking in anxiety in murine modeling. Handbook of the Biology and Pathology of Mental Disorders. Springer, pp 379\u2013399","DOI":"10.1007\/978-3-031-73368-0_15"},{"key":"2295_CR402","doi-asserted-by":"publisher","unstructured":"Wu Y (2025) The Role of BCAP in Regulating the TLR Signalling Pathway.[Apollo - University of Cambridge Repository]. https:\/\/doi.org\/10.17863\/CAM.119477","DOI":"10.17863\/CAM.119477"},{"issue":"1","key":"2295_CR399","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1038\/s41467-020-17756-7","volume":"11","author":"H Wu","year":"2020","unstructured":"Wu H, Estrella V, Beatty M, Abrahams D, El-Kenawi A, Russell S, Moshnikova A (2020) T-cells produce acidic niches in lymph nodes to suppress their own effector functions. Nat Commun 11(1):4113","journal-title":"Nat Commun"},{"key":"2295_CR398","doi-asserted-by":"publisher","first-page":"1613878","DOI":"10.3389\/fimmu.2025.1613878","volume":"16","author":"D Wu","year":"2025","unstructured":"Wu D, Xu-Monette ZY, Zhou J, Yang K, Wang X, Fan Y, Young KH (2025a) CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon. Front Immunol 16:1613878","journal-title":"Front Immunol"},{"issue":"7","key":"2295_CR400","doi-asserted-by":"publisher","first-page":"9338","DOI":"10.1007\/s12035-025-04834-4","volume":"62","author":"J-W Wu","year":"2025","unstructured":"Wu J-W, Wang B-X, Shen L-P, Chen Y-L, Du Z-Y, Du S-Q, Zhao X-D (2025b) Investigating the potential therapeutic targeting of the JAK-STAT pathway in cerebrovascular diseases: opportunities and challenges. Mol Neurobiol 62(7):9338\u20139364","journal-title":"Mol Neurobiol"},{"issue":"1","key":"2295_CR401","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5114\/fn.2025.149473","volume":"63","author":"J Wu","year":"2025","unstructured":"Wu J, Li X, Peng J, Fu W, Chen S, Wu H (2025c) Treatment update for autoimmune\/immune-mediated central nervous system diseases. Folia Neuropathol 63(1):19\u201329","journal-title":"Folia Neuropathol"},{"key":"2295_CR403","doi-asserted-by":"crossref","unstructured":"Xiang S, Shan Y, Xu S, Wang J, Luo M, Zhou J, Chen Q (2025) Cardiovascular disease meets cancer: exploring the epidemiology in china and homotherapy targeting intersectional mechanisms. Adv Sci, 12(37), e01820","DOI":"10.1002\/advs.202501820"},{"issue":"1","key":"2295_CR404","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-025-02142-w","volume":"10","author":"C Xue","year":"2025","unstructured":"Xue C, Chu Q, Shi Q, Zeng Y, Lu J, Li L (2025) Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances. Signal Transduct Target Therapy 10(1):106","journal-title":"Signal Transduct Target Therapy"},{"issue":"4","key":"2295_CR405","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/hdi.13272","volume":"29","author":"S Yadigar","year":"2025","unstructured":"Yadigar S, Halil GS, \u00d6zdemir P, \u00d6zdemir E, G\u00fcner EG, Demir AE, Y\u0131ld\u0131z M (2025) Three dimensional speckle tracking echocardiography in hemodialysis patients. Hemodial Int 29(4):588\u2013598","journal-title":"Hemodial Int"},{"key":"2295_CR407","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.clim.2016.09.014","volume":"189","author":"Z Yan","year":"2018","unstructured":"Yan Z, Gibson SA, Buckley JA, Qin H, Benveniste EN (2018) Role of the JAK\/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases. Clin Immunol 189:4\u201313","journal-title":"Clin Immunol"},{"key":"2295_CR406","doi-asserted-by":"crossref","unstructured":"Yan J, Fu P, Yang C, Xu Y, Liu Q, Choi K, Li Z (2026) Co-occurrence of lung adenocarcinoma with rapidly progressive dementia and multiple cerebral microbleeds: a case report. J Med Case Rep","DOI":"10.1186\/s13256-026-05846-x"},{"key":"2295_CR408","doi-asserted-by":"publisher","first-page":"1013933","DOI":"10.3389\/fnmol.2022.1013933","volume":"15","author":"J Yang","year":"2022","unstructured":"Yang J, Ran M, Li H, Lin Y, Ma K, Yang Y, Yang S (2022) New insight into neurological degeneration: inflammatory cytokines and blood\u2013brain barrier. Front Mol Neurosci 15:1013933","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"2295_CR409","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/acn3.70042","volume":"12","author":"S Yang","year":"2025","unstructured":"Yang S, Zhang TX, Liu J, Liu Z, Zhu L, Li YY, Zhang C (2025) Reconstitution of CXCR3\u2009+\u2009CCR6+ Th17. 1-Like T cells in response to ofatumumab therapy in patients with multiple sclerosis. Ann Clin Transl Neurol 12(5):1043\u20131053","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2295_CR410","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s40164-024-00583-7","volume":"13","author":"P Yao","year":"2024","unstructured":"Yao P, Liu Y-G, Huang G, Hao L, Wang R (2024) The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances. Experimental Hematol Oncol 13(1):118","journal-title":"Experimental Hematol Oncol"},{"issue":"76","key":"2295_CR411","doi-asserted-by":"publisher","first-page":"eabo0777","DOI":"10.1126\/sciimmunol.abo0777","volume":"7","author":"J Yi","year":"2022","unstructured":"Yi J, Miller AT, Archambault AS, Jones AJ, Bradstreet TR, Bandla S, Fremont DH (2022) Antigen-specific depletion of CD4\u2009+\u2009T cells by CAR T cells reveals distinct roles of higher-and lower-affinity TCRs during autoimmunity. Sci Immunol 7(76):eabo0777","journal-title":"Sci Immunol"},{"issue":"6","key":"2295_CR412","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, Zhang T (2019) A safe and potent anti-CD19 CAR T cell therapy. Nat Med 25(6):947\u2013953","journal-title":"Nat Med"},{"issue":"1","key":"2295_CR413","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41467-025-56097-1","volume":"16","author":"S-H Yoon","year":"2025","unstructured":"Yoon S-H, Kim Cy, Lee E, Lee C, Lee K-S, Lee J, Kim J (2025) Microglial NLRP3-gasdermin D activation impairs blood-brain barrier integrity through interleukin-1\u03b2-independent neutrophil chemotaxis upon peripheral inflammation in mice. Nat Commun 16(1):699","journal-title":"Nat Commun"},{"issue":"7","key":"2295_CR414","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/2159-8290.CD-21-1683","volume":"12","author":"RM Young","year":"2022","unstructured":"Young RM, Engel NW, Uslu U, Wellhausen N, June CH (2022) Next-generation CAR T-cell therapies. Cancer Discov 12(7):1625\u20131633","journal-title":"Cancer Discov"},{"issue":"9","key":"2295_CR415","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1111\/apt.70020","volume":"61","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Razavi H, Sherman M, Allen AM, Anstee QM, Cusi K, Schuppan D (2025) Addressing the high and rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction\u2010associated steatohepatitis (MASH): from the growing prevalence to payors\u2019 perspective. Aliment Pharmacol Ther 61(9):1467\u20131478","journal-title":"Aliment Pharmacol Ther"},{"key":"2295_CR416","doi-asserted-by":"publisher","unstructured":"Yousefi-Hashemabad MJ, Kamroo A, Rezvanimehr A, Saleki K, Barootchi E, Mehrani A, Kordi A, Saleki A, Zamani P, Bazdar A, Nateri AS, Barootchi S, Rezaei N (2026) CD47\/SIRP\u03b1 Immune Checkpoint Modulation: A Synergistic Strategy for Next-Generation CAR Therapies. Mol Cancer Ther 25(6):912-923. https:\/\/doi.org\/10.1158\/1535-7163.MCT-25-0531","DOI":"10.1158\/1535-7163.MCT-25-0531"},{"issue":"6","key":"2295_CR417","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.ymthe.2024.11.013","volume":"33","author":"Q Yu","year":"2025","unstructured":"Yu Q, Wang D, Li Z, An N, Li C, Bao Y, Jiang L (2025) Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed\/refractory multiple myeloma. Mol Ther 33(6):2768\u20132777","journal-title":"Mol Ther"},{"key":"2295_CR418","doi-asserted-by":"publisher","unstructured":"Zeynodini Meimand H, Anbarloui MR, Eslamian M, Rasouli HR, Ahmadpour F (2025) Evaluation of betaxolol in improving the glasgow outcome scale extended (GOSE) of the acute phase of patients with mild to moderate Traumatic Brain Injury: a double blinded randomized clinical trial. Neurol Res  23:1-14. https:\/\/doi.org\/10.1080\/01616412.2025.2578346","DOI":"10.1080\/01616412.2025.2578346"},{"issue":"1","key":"2295_CR425","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s44272-025-00044-0","volume":"4","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Han W (2025) Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review. Clin Cancer Bull 4(1):15","journal-title":"Clin Cancer Bull"},{"key":"2295_CR419","doi-asserted-by":"publisher","first-page":"724211","DOI":"10.3389\/fimmu.2021.724211","volume":"12","author":"A Zhang","year":"2021","unstructured":"Zhang A, Sun Y, Du J, Dong Y, Pang H, Ma L, Yue Y (2021) Reducing hinge flexibility of CAR-T cells prolongs survival in vivo with low cytokines release. Front Immunol 12:724211","journal-title":"Front Immunol"},{"issue":"1","key":"2295_CR423","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xiao D, Mao Q, Xia H (2023a) Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Therapy 8(1):267","journal-title":"Signal Transduct Target Therapy"},{"key":"2295_CR426","doi-asserted-by":"publisher","first-page":"1281763","DOI":"10.3389\/fncel.2023.1281763","volume":"17","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Duan Z, Cui Y (2023b) CD8\u2009+\u2009T cells in brain injury and neurodegeneration. Front Cell Neurosci 17:1281763","journal-title":"Front Cell Neurosci"},{"issue":"7","key":"2295_CR421","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00277-024-05640-z","volume":"103","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Zhu X, Xiao Y (2024a) The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. Ann Hematol 103(7):2197\u20132206","journal-title":"Ann Hematol"},{"issue":"8","key":"2295_CR422","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.hlife.2024.05.005","volume":"2","author":"W Zhang","year":"2024","unstructured":"Zhang W, Liu D, Zhang T, Cao J, Wang G, Li H, Li J (2024b) BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. hLife 2(8):434\u2013438","journal-title":"hLife"},{"issue":"14","key":"2295_CR420","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/1750743X.2025.2560798","volume":"17","author":"H Zhang","year":"2025","unstructured":"Zhang H, Gao J, Zhang Z, Zhang B (2025) Current status of chimeric antigen receptor T cell therapy and its exhaustion mechanism. Immunotherapy 17(14):1039\u20131057","journal-title":"Immunotherapy"},{"key":"2295_CR424","doi-asserted-by":"publisher","first-page":"175628642514044","DOI":"10.1177\/17562864251404455","volume":"19","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Dobson R, Giovannoni G (2026) Comorbidity and modifiable risk factors in multiple sclerosis. Ther Adv Neurol Disord 19:17562864251404455","journal-title":"Ther Adv Neurol Disord"},{"key":"2295_CR428","doi-asserted-by":"publisher","first-page":"116439","DOI":"10.1016\/j.bcp.2024.116439","volume":"227","author":"W Zhao","year":"2024","unstructured":"Zhao W, Yao Y, Li Q, Xue Y, Gao X, Liu X, Sun S (2024) Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy. Biochem Pharmacol 227:116439","journal-title":"Biochem Pharmacol"},{"key":"2295_CR427","doi-asserted-by":"publisher","first-page":"1685316","DOI":"10.3389\/fimmu.2025.1685316","volume":"16","author":"P Zhao","year":"2025","unstructured":"Zhao P, Guan C, Lu J, Zhang Y, Wang B, Huang L, Xu P (2025) Global, regional, and national trends and burden of multiple sclerosis in adolescents and young adults: a data analysis from 1990 to 2021 and projections to 2040. Front Immunol 16:1685316","journal-title":"Front Immunol"},{"issue":"5","key":"2295_CR429","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","volume":"32","author":"W Zheng","year":"2018","unstructured":"Zheng W, O\u2019Hear CE, Alli R, Basham JH, Abdelsamed HA, Palmer LE, Geiger TL (2018) PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia 32(5):1157\u20131167","journal-title":"Leukemia"},{"issue":"1","key":"2295_CR430","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J (2024) Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discovery 10(1):318","journal-title":"Cell death discovery"},{"key":"2295_CR431","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"J-e Zhou","year":"2022","unstructured":"Zhou J-e, Sun L, Jia Y, Wang Z, Luo T, Tan J, Yu L (2022) Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Controlled Release 350:298\u2013307","journal-title":"J Controlled Release"},{"issue":"1","key":"2295_CR432","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41419-025-07893-6","volume":"16","author":"W Zhou","year":"2025","unstructured":"Zhou W, Xia S, Wang C, Yang Q, Verkhratsky A, Niu J (2025) Critical analysis of translational potential of rodent models of white matter pathology across a wide spectrum of human diseases. Cell Death Dis 16(1):580","journal-title":"Cell Death Dis"},{"issue":"11","key":"2295_CR433","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s40265-025-02212-x","volume":"85","author":"L Zuroff","year":"2025","unstructured":"Zuroff L, Farkhondeh V, Bove R, Green AJ, Zuroff et al (2025) Drugs, 85(11), 1337\u20131362","journal-title":"Drugs"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02295-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02295-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:02:28Z","timestamp":1784980948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02295-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":433,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2295"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02295-2","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}